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2Abstract
Introduction:  To reduce overdiagnosis, we need accurate methods to quantify and monitor this
phenomenon over time.
Aims: To systematically review the methods that have been used for measuring overdiagnosis from
cancer screening; to evaluate the strengths and weaknesses of each method.
Methods: We searched PUBMED, EMBASE, and the Cochrane Library for primary research studies of
any design that quantified overdiagnosis from cancer screening. We abstracted relevant data and
appraised study design and methods using established criteria.
Results:  49 studies met inclusion criteria. We grouped studies into four methodologic categories and
found strengths and weaknesses with all designs. (1) Follow-up of a well-designed RCT (n=1) is
theoretically an ideal method but requires substantial time, may not be generalizable, and is not suitable
for monitoring. (2) Pathologic/imaging studies (n=8) that draw conclusions about overdiagnosis by
examining the range of biological or behavioral characteristics among cancers are simpler in design but
assume that these characteristics are highly correlated with progression. (3) Modeling studies (n=19) can
be done in a shorter time frame but require complex mathematical equations simulating the natural history
of screen-detected cancer, which is the fundamental unknown question.  (4) Ecologic studies (n=21) are
limited by a lack of agreed-upon standards, by variable data quality, by inadequate follow-up time, and by
the potential for population-level confounders. Some ecologic studies, however, have used excellent
methods; several of these studies from different geographic areas may together provide the best overall
estimate of overdiagnosis and are ideal for monitoring it over time.
Conclusions:  Well-conducted ecologic studies in multiple settings should be used for quantifying and
monitoring overdiagnosis in cancer screening programs. To support this work, we need internationally
agreed-upon standards for ecologic studies and a multi-national team of unbiased researchers to perform
analysis.
3Introduction
A critical part of medical decision-making regarding whether or not to be screened for cancer is
determining the balance of benefits and harms of screening programs.  An appropriate cancer screening
program is one for which the potential benefits outweigh the potential harms.  While the exact point for
which benefits outweigh harms or vice-versa is based on a complex judgment and may differ among
individual patients, health care providers and policy-makers, this determination requires an accurate
assessment of the magnitude of such benefits and harms.1
A harm of cancer screening that is increasingly being recognized and reported is overdiagnosis.
Overdiagnosis refers to the diagnosis of a condition that would have otherwise not resulted in any
symptoms or death during the patient’s lifetime.  In cancer, there are different scenarios that can lead to
overdiagnosis.  First, overdiagnosis can occur because of characteristics of the tumor and its potential for
growth and regression.  A tumor can either grow so slowly that the patient never would have developed
symptoms or in some cases it can actually regress.  Alternatively, overdiagnosis can result from the
diagnosis of a cancer that progresses at a rate such that the patient ends up dying from another cause
before the cancer becomes symptomatic. Consideration of competing mortality is important in cases of
this second type of overdiagnosis, as the degree of medical comorbidity may contribute to the likelihood
of death from another cause.2
Many consider overdiagnosis to be the most serious side effect of cancer screening, as
overdiagnosis results in erroneous labeling of the patient with an incorrect life-long diagnosis. The
resulting treatments and surveillance as well as the label of cancer itself cause physical and psychosocial
harm to patients.3 Physicians cannot distinguish between a patient with a cancer destined to cause harm
and an overdiagnosed cancer at the time of diagnosis, so essentially all cancers are treated. A patient who
is overdiagnosed with cancer cannot benefit from this diagnosis or treatment but instead can only be
harmed.4
4Potential for Overdiagnosis:  Early Stage Disease Reservoir
The existence of overdiagnosis requires that there be a reservoir of non-progressive or slowly
progressive disease in the population that can be detected with diagnostic tests, or a subset of cancers that
are currently present that will later regress, or likely both. There are biologic mechanisms that enable
cancers to be non-progressive, such as a cancer that outgrows its blood supply, that is recognized and
successfully contained by the host immune system, or that simply lacks typical aggressive
characteristics.4 Autopsy studies have been used to investigate whether a reservoir of undetected cancer
exists in patients who died from other causes.
A review of autopsy studies of women not known to have breast cancer during their lives found
the median prevalence of breast cancer in seven studies among women of all ages was 1.3%, and the
median prevalence of ductal carcinoma in situ (DCIS) was 8.9%. The prevalence of breast cancer or
DCIS among women of screening age ranged from 7% to 39%. The authors observed that prevalence
was correlated with the degree of rigor of the observation, as studies that used more slides to examine the
tissues found a higher prevalence, which may explain the large variation in estimates.5 Studies that follow
patients who were initially misdiagnosed with benign lesions who were actually confirmed later to have
DCIS also provide the some direct evidence about the progression of DCIS to invasive cancer.  These
studies report a range of 14-53% progression of DCIS to invasive cancer over a period of ten years or
more.6 These studies provide evidence that a reservoir of undetected non-progressive breast cancer and
DCIS is likely present in some women, though the exact prevalence is uncertain.
Other autopsy studies provide further evidence of a disease reservoir in other cancer types as
well.  A retrospective study in Australia of over 13,000 autopsy reports of people who died from natural
causes found 47 cases of incidental lung cancer, 86% of which were stage one.7 Another study that
compared autopsy evaluation for pulmonary nodules with detection of the same nodules on CT scan in the
two months prior to death suggests this may be an underestimate.  This study investigated whether claims
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had found very low rates of malignant lung cancers in autopsy subjects.  Researchers found that 32% of
patients with pulmonary nodules identified on a thoracic CT within 2 months of deaths did not have these
same pulmonary nodules detected on autopsy, thus concluding that autopsy likely underestimates the
prevalence of clinically insignificant lung cancer.8 The age-independent frequency of histological
prostate cancer in an autopsy study of 212 patients without a history of prostate cancer was 18.8% and
ranged from 0% to 56% among different age groups.9 In another study, the overall prevalence of prostate
cancer was 37.3% in Russian men and 34.6% in Japanese men who died from causes other than prostate
cancer.  Prevalence was greater than 40% in men over 60 and greater than 60% in men over 80,
demonstrating a large early-stage disease reservoir that increase with age.10 Finally, a study of incidental
thyroid cancer in Finland found a papillary thyroid carcinoma prevalence of 35.6% among autopsy
patients.  Many of the carcinoma specimens were smaller than the width of each slide (2.5mm) leading to
the conclusion that the investigators had likely missed cases.11
Potential for Overdiagnosis:  Cancer Regression
The ability of tumors to regress has been documented in cases reports throughout the medical
literature for a variety of cancer types.  In breast cancer, a 1999 review identified 32 cases of reported
spontaneous remission of breast cancer12, and another case report of has been published since the
review.13 A 2009 review found 76 reported cases of spontaneous regression of metastatic melanoma
since 1866.14 During a randomized controlled trial of interferon-beta for metastatic renal cell carcinoma,
six patients of 99 in the control group achieved remission, including three whose cancer had completely
regressed.15 Spontaneous regression of hepatocellular carcinoma has been documented 75 times in the
medical literature.16 In a Japanese screening program, patients with localized, low-risk neuroblastoma
were offered the option of observation instead of treatment.  Eleven patients were identified for
observation and all eleven of the tumors decreased in size.17 In another study of neuroblastoma, 93
patients with low-risk disease were observed, and 44 of these tumors regressed with complete regression
6in 17 patients by 20 months following diagnosis.18 Other studies indicate the potential for lesions
typically considered as “pre-cancerous” to regress, including polyps19 and cervical low-grade squamous
intraepithelial lesions.20
Another study demonstrated the potential for regression of breast cancer using different methods.
This study compared breast cancer incidence in four counties of Norway in a group of women invited for
three rounds of screening from 1996-2001 to an age-matched control group that was monitored from
1992-1997 and then offered one-time screening at the end of the observation period. Potential
confounders including educational attainment, family income, reproductive history and screening
attendance were all closely matched between the two groups.  Before the control group was invited for
screening, the cumulative incidence of breast cancer was significantly higher in the screened group (RR
1.57, 95% CI 1.44-1.70).  However, contrary to what would be expected, the cumulative incidence of
breast cancer remained elevated by 22% in the screened group compared to the control group after the
control group underwent prevalence screening after the observation period (RR 1.22, 95% CI 1.16-1.30).
This finding suggests that the natural history of some screen-detected breast cancers is to regress, as some
of the cancers detected on repeated mammography would not have been detectable at the end of the 6-
year screening period.  The authors of this study also noted that the Canadian randomized controlled trial
of breast cancer screening in women aged 40 to 4921 also reported a 22% excess of incidence in the
screened group that was not detected in the control group despite four years of screening at the end of the
trial.22
Increasing Incidence of Early Stage Cancers
A pattern of increasing incidence of early stage cancer, especially that corresponds temporally
with screening, is indicative of possible overdiagnosis.  In the United States, several types of cancer have
had dramatic increases in incidence over the past decades. Melanoma incidence increased 2.5-fold in
patients over 65 between 1986 and 2001.  After accounting for a possible increase in the true incidence of
melanoma for alternative reasons, researchers found that the increase in incidence was associated with the
7increase in biopsy rate over the same time frame and that the majority of new cases were confined to early
stage disease.23 Other studies found similar growth, but some also found an increase in the incidence in
late-stage, thicker melanomas and thus concluded that the increase in incidence cannot be entirely
attributed to increased detection of early-stage lesions.24 Similarly, thyroid cancer incidence increased
2.6-fold from 1973 to 2006.  The greatest growth, of 441%, was seen in the smallest subset of papillary
thyroid cancer tumors less than 1centimeter.  However, larger tumors also increased leading some
researchers to argue that the increasing incidence of thyroid cancer is not entirely due to an increase in
early lesions.25 Some types of overdiagnosis may not be due to screening, but actually to the increased
use of imaging tests such as abdominal CT scans.  Incidence rates of localized renal cell carcinoma more
than doubled from 1988 to 2006, from 3.8 per 100,000 person-years to 8.2 per 100,000 person-years.26
Some types of cancer are currently decreasing in incidence despite having increased greatly over
the past few decades.  Prostate cancer incidence has dropped slightly in recent years after increasing
dramatically from 1986 to 1992 with the introduction of PSA screening. However, the relative incidence
rates of prostate cancer in 2005 relative to 1986 varied widely by age group, with relative rates of 3.64 in
men ages 50 to 59 and 7.23 in men younger than 50, so in some demographics incidence is still on the
rise.27 Breast cancer incidence but sustained a sharp increase between 1980 and 1987 corresponding with
increasing use of screening mammography.  During this period, incidence of breast cancers smaller than
one centimeter quadrupled, from 9 per 100,000 to 36 per 100,000, and incidence of DCIS more than
tripled from 4 per 100,000 to 15 per 100,000.28 Breast cancer incidence then decreased in the 1990’s and
early 2000’s but since 2006 has been again increasing.29 Another recent study spanning a longer time
frame found that the incidence of early stage breast cancer more than doubled from 112 cases per 100,000
to 234 per 100,000 from 1976 to 2008.30
Patterns of cancer incidence and mortality in the United States demonstrate that overdiagnosis is
occurring.  A cancer with both increasing incidence and increasing mortality represents a true increase in
cases of that type of cancer.  However, a cancer with increasing incidence but mortality that remains
unchanged over the same time period likely indicates overdiagnosis.4 This pattern has been seen over the
8past 30 years in the United States with melanoma, breast cancer, prostate cancer, kidney cancer, and
thyroid cancer.  An alternative explanation for this pattern is that improvements in diagnosis and
treatment of the cancer are causing an improvement in mortality that exactly counteracts the increase in
incidence.  However, this explanation involves more assumptions than are required for the explanation
involving overdiagnosis and as such is less likely.4
Addressing Overdiagnosis
Experts have suggested a variety of strategies for addressing the problem of overdiagnosis in
cancer.  Several have proposed raising the threshold for labeling a test result or image abnormal and
consider monitoring lesions over time to assess growth instead of jumping straight to a bipsy.4,31,32 Others
advise replacing the term cancer with another term that suggests the more benign nature of much of the
spectrum of cancer to represent early-stage lesions.32 Eventually, we may have biomarkers that can
distinguish between indolent and more aggressive cancers such that therapies can be targeted towards
those cancers most likely to be fatal.
Education about overdiagnosis will also be crucial for minimizing its harms4,31, and this includes
education for medical students, residents, current physicians, and the public.  Medical practitioners
currently receive mixed messages regarding overdiagnosis, however, as its coverage and emphasis in the
medical literature, as well as estimates of its magnitude, have varied widely.  A 2007 study found unequal
attention given to benefits and harms in articles on screening mammography, which was related to the
professional affiliation of the author.  Benefits were mentioned more often than harms (96% versus 62%),
with 38% of articles mentioning only benefits.  Overdiagnosis was mentioned in only 40% of articles on
screening mammography and was more likely to be downplayed or rejected by authors that worked
specifically in screening (40%) than by authors in screening-affiliated specialties (like breast cancer
surgery or radiology) who were not working directly with screening (17%) or by authors in an unrelated
specialty (7%).33 Within the medical community, overdiagnosis is a polarizing issue, and the lack of
clarity in communication about overdiagnosis or understanding of its magnitude is a barrier to effectively
addressing it.
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overdiagnosis, which likely will follow an effort to educate patients so they are able to make informed
decisions. Currently, knowledge of overdiagnosis among the public appears to be minimal.  In a cross
sectional study (Schwartz et al) of US women’s attitudes regarding potential consequences of breast
cancer screening, no women identified the detection or treatment of a non-progressive breast cancer as a
potential harm of screening, and only 7% were aware of the existence of non-progressive breast cancer.34
A recent qualitative study35 of women’s values regarding overdiagnosis reported that women had minimal
awareness of overdiagnosis prior to participation in the study, and some expressed surprise at being
informed of it. Despite low awareness, women from various socioeconomic and educational backgrounds
could understand information presented on overdiagnosis and valued this information in making their
screening decisions.35 Other studies confirm that the public values information on overdiagnosis as a
harm of screening.  In the Schwartz et al study, 60% of women wanted to factor information on non-
progressive cancers into their decisions for pursuing mammography.34 A 2013 study of men’s
preferences for prostate cancer screening found that men considered risk of unnecessary treatment and
biopsy as a factor in decision-making.36
In the preliminary Hersch et al study, the magnitude of overdiagnosis also appeared to be
valuable to women making decisions about screening mammography.  When the estimate of
overdiagnosis was 50%, some women expressed that they would much more carefully consider the
decision to be screened, with some women expressing that they would likely forego screening altogether,
be less concerned about achieving a rigid screening interval, or consider delaying screening until a later
age.  At lower estimates, women were less concerned about overdiagnosis.  With overdiagnosis of 1 to
10%, some women expressed that this was minimal and would not at all affect their intentions for
screening. With overdiagnosis of 30%, women acknowledged concern with this large number and effect
on people’s lives, but many indicated that they would probably still continue to undergo screening.35
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Both the existence and magnitude of overdiagnosis are important to patients, and its magnitude
can be critical for decision-making on a population level as well.  In evaluating screening programs,
experts argue that benefits and harms should be weighed using an outcomes table which depicts all the
possible outcomes of a screening test and their relative likelihoods among an eligible cohort1.  Critical
policy decisions regarding provision of screening are made based on an often delicate balance of benefits
and harms, and a change in the magnitude of overdiagnosis can shift this balance one way or another.
Thus, accurate measurement of overdiagnosis is important for both individual and population-level
decision-making.
Unfortunately, because it is impossible to distinguish at the time of diagnosis between an
overdiagnosed cancer and one that would have become clinically meaningful, the measurement of
overdiagnosis is not straight-forward.  Researchers have used various methods to indirectly quantify
overdiagnosis resulting from cancer screening, but the magnitudes of such estimates have varied widely.
This systematic review attempts to identify and evaluate the methods that have been used for measuring
overdiagnosis resulting from cancer screening and analyze the advantages and disadvantages of each
method.  We will also determine which methods for measuring overdiagnosis are most suitable for
monitoring it over time, as monitoring will be key to preventing overdiagnosis and tracking our progress
with this endeavor.  A better understanding of methods for measuring overdiagnosis will aid future
researchers in designing studies to accurately measure this phenomenon.  In turn, more reliable and
accurate measurements of overdiagnosis resulting from cancer screening will enable better representation
of the benefits and harms of such tests, ultimately providing the tools for patient-centered medical
decision-making. Finally, as we develop interventions to try to decrease overdiagnosis, we need to be
able to perform surveillance and monitor overdiagnosis over time, which requires accurate and reliable
methods for measurement.
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Methods
Key Questions
This review aims to answer the following key questions:
Key Question 1:  What research methods have been used to measure overdiagnosis resulting from cancer
screening tests?
Key Question 2:  What are the advantages and disadvantages of each method of measuring
overdiagnosis?
Key Question 3:  What methods would be most suitable for monitoring overdiagnosis over time?
Eligibility Criteria
We designed inclusion and exclusion criteria for the review to include all studies that have
attempted to measure, quantify, or estimate the amount of overdiagnosis resulting from a cancer screening
test in an asymptomatic adult population.  We used modified PICOTS criteria (see Table 1) whereby the
population of interest was studies that measure overdiagnosis.  We limited the scope of the review to
studies of overdiagnosis in the nine types of solid tumors with the highest incidence in the United States
in 2012, as these cancer types likely have the highest potential for overdiagnosis due to a high rate of
cases diagnosed.  These cancer types are prostate, breast, lung, colorectal, melanoma, bladder, renal,
thyroid, and uterine cancer.37 Studies reporting overdiagnosis not relating to cancer were excluded, as
were studies that addressed the potential for overdiagnosis but did not report a quantity.  For example,
autopsy studies reporting on the prevalence of low grade or early stage cancer in patients who died of
other causes are important for demonstrating the principles of overdiagnosis but were ineligible for this
review.  Studies that examined biologic or behavioral characteristics of detected tumors and then drew
conclusions about an amount of overdiagnosis were included.  Outcomes of interest included the
estimated magnitude from each type of measurement, as well as the way the measurement was calculated.
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Studies not providing a numerical estimate for the magnitude of overdiagnosis were excluded. Studies
from any setting and time frame were included.  Because measuring overdiagnosis is possible through a
variety of study designs,  and because the comparison of methods was the key intention of this review, a
wide range of study designs were eligible including randomized controlled trials, prospective or
retrospective cohort studies, ecologic studies, and case control studies. When multiple publications that
measured overdiagnosis with modeling used the same model and populations to determine the
overdiagnosis estimate, only the most recent publication was included. Non-systematic and systematic
reviews, case reports and case series were excluded.  Only studies in English were included.
Search Strategy
We conducted a systematic search of PUBMED, EMBASE, and the Cochrane library on
February 22, 2013.  A research librarian helped with the development of the search terms and the
adaptation of the terms to the different databases.  The search terms used to search PubMed were as
follows:  “(cancer*[tw] OR neoplasms[MeSH]) AND (Screening*[tw] OR early diagnos*[tw] OR early
detect*[tw]) AND (overdiagnos*[tw] OR over diagnos*[tw] OR overdetect*[tw] OR over detect*[tw])”.
We placed no date or language limitations on studies to avoid missing studies that had not yet been
indexed.  We also hand-searched reference lists of included systematic reviews and other narrative
reviews identified during the initial search for additional relevant studies.
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Table 1:  Modified PICOTS Criteria for Study Eligibility
Include Exclude
Population Studies that attempt to measure, estimate,
or quantify the amount of overdiagnosis
resulting from a cancer screening test in
an asymptomatic population
Cancer types eligible for inclusion:
prostate, breast, lung, colon, melanoma,
bladder, renal, thyroid, uterine
Studies that look at biologic or behavioral
characteristics of tumors (i.e., grade,
doubling time) and draw conclusions
about an amount of overdiagnosis
Studies reporting overdiagnosis not related
to cancer screening or related to a type of
cancer screening not listed in the inclusion
criteria
Studies addressing the potential for
overdiagnosis but that do not draw
conclusions regarding an amount of
overdiagnosis (for example, studies that
report on prevalence of early stage cancer
detected at autopsy)
Studies investigating different thresholds
for tumor markers that comment on
implications for overdiagnosis
Studies performed in a symptomatic
population
Intervention Method for measuring, estimating, or
quantifying overdiagnosis
Outcome Magnitude of overdiagnosis Studies that do not report a magnitude of
overdiagnosis
Time Frame Studies performed over any time frame
Setting Any setting
Study Design Randomized controlled trials, prospective
or retrospective cohort studies, ecologic
studies, case control studies, modeling
studies
Non-systematic and systematic reviews,
case reports, case series
Study Selection
Titles and abstracts of all studies identified by the search were reviewed independently by two
reviewers for inclusion based on the criteria discussed and listed in Table 1.  Any article that was
identified for inclusion by either reviewer or for which there was not enough information available in the
abstract had its full text reviewed for the same eligibility criteria.  Two reviewers independently
determined whether the identified studies could be verified for inclusion by analyzing the full texts.  Any
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disagreements about inclusion or exclusion of these studies were resolved by consensus, and a third senior
reviewer was consulted to resolve any remaining disagreements.
Data Extraction
One reviewer extracted relevant data on a spreadsheet that was standardized for each type of
study.  These data were then verified by a second reviewer, and discrepancies were resolved by
consensus.  For all study types, information on study design, study population, time period, screening test,
screening schedule, threshold for labeling a result abnormal, length of follow-up, magnitude of
overdiagnosis, and conclusions were extracted.  If studies used modeling to measure overdiagnosis,
information on the name and type of model, data sources, and sensitivity analyses were extracted.  For
cohort and ecologic studies, information on the reference population and statistical adjustment for
confounders and lead time were noted.  When randomized trials were followed-up to measure
overdiagnosis, the type of statistical analysis performed and the baseline characteristics of the two groups
were extracted. Some studies used information on pathologic or imaging characteristics of cancers to
draw conclusions about overdiagnosis, and the details of these characteristics were documented for these
studies.
All studies were assessed for reporting of the preferred outcome, which was overdiagnosis
defined as excess of cancer cases diagnosed during the screening period divided by total number of cases
detected by screening.  This method is the most appropriate way to calculate overdiagnosis, as
overdiagnosis is an outcome of screening and can only occur in asymptomatic patients diagnosed by
screening.  Using a different denominator, such as the total number of cancer cases detected including
interval cancers diagnosed by the presence of symptoms, dilutes the overdiagnosis measurement and
makes its implications less clear. The timeframe over which overdiagnosis is measured can also affect its
magnitude, and we made note of this timeframe in our data extraction. We extracted the preferred
outcome from all studies that reported it, and we calculated it using data provided in the paper when it
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was available.  Otherwise, we extracted the overdiagnosis measurement that was reported but made note
of the way the calculation was performed.
Risk of Bias Assessment
We created standard criteria to evaluate risk of bias for each of the four main types of studies
found in this review, which were cohort and ecologic studies, pathologic and imaging studies, follow-up
of randomized controlled trials, and modeling studies. We rated each individual study for risk of bias
using ratings of high, moderate or low.  Two reviewers independently rated the risk of bias for each study,
and we resolved discrepancies by consensus.  The four sets of complete criteria used for risk of bias
assessment can be found in Appendix A.
We adapted the criteria for cohort and ecologic studies from quality criteria used in a recent
systematic review of observational studies of breast cancer screening.38 These adapted criteria include the
potential for selection bias, measurement bias, and confounding with a focus on the use of comparable
groups with regards to potential confounders. Risk of bias criteria for randomized controlled trial follow-
up studies were adapted from standard criteria used by the USPSTF.39 Pathologic and imaging studies
typically did not have a control group, so the risk of bias assessment focused on the validity and reliability
of the measurements performed. The appropriateness of the time frame was evaluated for all study types,
as the measurement of overdiagnosis requires consideration of the lead time of the cancers studied, and
measuring overdiagnosis without adequate time for follow-up can affect its magnitude.
We developed a new set of criteria for evaluating modeling studies for the purpose of this review.
Authors of modeling studies were expected to discuss the probability for biases in the data used in the
model and to choose data that had low probability for biases.  Assumptions were to be clearly stated,
ideally in a table of assumptions, and all assumptions made in the model needed to be backed with
evidence that was ideally identified and assessed for quality in a systematic review.  Sensitivity analyses
should have been performed for any uncertain variables, ideally with probabilistic multivariate sensitivity
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analyses rather than single-variable analyses. Finally, models should also have been validated using
population data different from the data used to calibrate the model.
Strength of Evidence Assessment
To evaluate the strength of evidence, we developed a set of criteria from other criteria used by the
USPSTF39 and by the GRADE working group.40 Each individual study was evaluated for risk of bias,
directness, external validity, and precision. We rated each study as high, moderate or low for risk of bias
and good, fair, poor, or “cannot determine” for the other criteria. Among ecologic and cohort studies,
each study was also reviewed for the appropriateness of the analysis and its ability to provide an unbiased
overdiagnosis estimate, which will be discussed further in the results section. Two reviewers individually
determined ratings for each of these criteria, and we resolved discrepancies by consensus.
The GRADE working group defined directness as the extent to which the intervention relates the
evidence to health outcomes.40 In this review, we evaluated the extent to which the evidence links the
screening test directly to health outcomes without making certain assumptions, including assumptions
regarding the progression of a screen-detected cancer to cancer-related morbidity and mortality, and
assumptions regarding the association of pathologic or behavioral characteristics of a cancer with cancer
progression, morbidity and mortality.  A study with good directness requires minimal assumptions to
draw conclusions about the magnitude of overdiagnosis and directly measures excess cases of cancer.
We adapted criteria for evaluating external validity of individual studies from the USPSTF
procedure manual.39 Studies were assessed for their relevance to a general US adult population.  We
considered the extent to which the study population was similar to the general US population in factors
associated with cancer incidence and in the quality of medical care and risks for competing mortality.  We
also assessed the similarity of the screening situation in each study to the way screening is performed in
the US, including the expertise of the radiographers, the quality of the screening facilities, and the
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threshold used to label a result abnormal.  All of these factors affect the way cancer is diagnosed and thus
can affect the degree of overdiagnosis present.
We combined the ratings for risk of bias, analysis, directness, external validity, and precision with
an evaluation of the consistency of the study results to determine of the strength of evidence for the
overall body of evidence. We evaluated strength of evidence for each study design and cancer type. The
risk of bias, directness, external validity, and precision of each of the individual studies was used to assess
the aggregate risk of bias, directness, external validity, and precision for the body of evidence. We used
the GRADE working group’s definition to evaluate consistency by looking at the degree to which the
overdiagnosis measurement from all the included studies of that cancer type and study design had the
same magnitude.  The complete list of criteria used to evaluate strength of evidence can be found in
Appendix B.
Data Synthesis and Analysis
We performed qualitative data synthesis, organizing the results by study design and cancer type.
We did not attempt to perform quantitative analysis because of the heterogeneity of the study designs,
populations, and results.  We identified strengths and weaknesses of each study design used to measure
overdiagnosis, based on the criteria used to evaluate the strength of the body of evidence. We did not
attempt to assess publication bias.
Results
Our search, performed on February 22, 2013, yielded a total of 1262 studies from PubMed,
EMBASE, and the Cochrane library.  After duplicates were removed, 823 studies remained, and five
additional studies were later identified by hand searching reference lists of relevant reviews.  We
reviewed 828 abstracts and identified 109 studies that were eligible for full-text review.  During the full-
text review process, 21 studies were excluded for wrong study design as they were non-systematic and
systematic reviews, 30 were excluded for not providing an estimate of the magnitude of overdiagnosis,
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Figure 1:  PRISMA Flow Diagram of Study Selection Process
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and one was excluded for not being in English.  All studies that used modeling to measure overdiagnosis
were again reviewed to see if there were any studies that used the same model and population as another
study.  We combined four of these modeling studies because they met these criteria, and in each case the
most recent publication was included. We excluded one additional modeling study for not including
invasive cancer. These modeling studies that provided an estimate of overdiagnosis magnitude but were
excluded for the reasons discussed are listed in Appendix C. Three studies of prostate cancer
overdiagnosis by the same group of authors41-43 used essentially identical methods and the same
population to study overdiagnosis defined based on pathologic criteria.  Of these three studies, only the
most recent publication41 was included. Finally, a cohort study of breast cancer overdiagnosis in
Florence44 was excluded because two other more recent studies by overlapping authors45,46 were available.
A total of 49 studies were included for qualitative synthesis. Figure 1 shows the flow diagram of the
study selection process based on PRISMA recommendations.47
The included studies fell into four categories.  Some studies used mathematical and statistical
models to measure overdiagnosis.  Other studies examined pathologic or imaging characteristics of
tumors and used information about these characteristics to draw conclusions about overdiagnosis.  A large
group of studies analyzed cancer incidence in either two populations or two cohorts to measure
overdiagnosis.  Finally, one study followed participants of a randomized-controlled trial for fifteen years
after the trial ended.  We categorized studies as modeling studies, pathologic/imaging studies, ecologic or
cohort studies, and follow-up of randomized controlled trials.
Characteristics of Included Studies: Modeling Studies
We included nineteen modeling studies in this review, including nine models of prostate cancer,
seven models of breast cancer, two models of lung cancer and one model of colon cancer overdiagnosis.
The characteristics of the included modeling studies are listed in Table 2, and full details are provided in
Appendix Table 2.  These studies modeled a variety of screening situations and schedules, with one
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study48 modeling 32 different hypothetical prostate screening schedules, for example.  Not all studies
modeled both the non-progressive disease and competing mortality components of overdiagnosis, as three
breast cancer studies49,50,51 did not include overdiagnosis resulting from competing mortality in their
models. One breast cancer model did not include DCIS.52 It is important to note that these studies
provide an incomplete look at overdiagnosis and almost certainly underestimate its magnitude to some
degree.
In contrast to the other study types, most modeling studies reported the preferred outcome, which
was the percentage of excess cancers divided by the total number of screen-detected cancers.  However, a
few studies instead reported an overdiagnosis measure that dilutes the estimate, such as lifetime risk of
overdiagnosis of prostate cancer reported by Gulati and colleagues.48 There was considerable variability
within and among modeling studies in estimates of overdiagnosis, with estimates of overdiagnosis as a
percentage of screen-detected prostate cancers ranging from 8.48% to 67% depending on model
parameters and screening and population details.  Many studies provided multiple estimates depending on
these various parameters to demonstrate the variability of the results. Among studies of breast cancer,
estimates of overdiagnosis as a percentage of screen-detected cancers ranged from 0.3% to 67.4%, though
these estimates were provided for specific time points such as the prevalence screen or the second screen
in a series of screens, which makes them difficult to interpret.
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Table 2:  Summary Evidence Table of Modeling Studies
Study;
Cancer type;
Model(s)
Modeled
population:
Country, ages;
Screening
schedule
Data Sources
a. Incidence
b. Mortality
c. Other
a. External
Validation?
b. Includes
Competing
Mortality?
c. Includes
DCIS?
Reports
Preferred
Outcome?
Magnitude of
Overdiagnosis
(95% CI)
Sensitivity
Analyses
varying mean
sojourn time
or lead time?
Overall
Risk of
Bias
Davidov 200453;
Prostate
US;
50 to 60, 70 or 80
at 5-year intervals
a. SEER1993-7
b. SSA life tables
a. No
b. Yes
c. n/a Unclear 8.48-53.6%
Univariate.
MST 5-15 years
Overdiagnosis
varied greatly
with MST. Moderate
Draisma 200954;
Prostate;
MISCAN,
FHCRC,
UMichigan
US, 54-80;
Typical US
screening patterns
a. SEER 1985-2000
b. Standard life tables
a. No
b. Yes
c. n/a Yes
MISCAN: 42%
FHCRC: 28%
UMich: 23% Not performed High
Gulati 201348;
Prostate;
FHCRC
US, 40;
32 screening
schedules
simulated
a. SEER 1975-2000
b. US life tables
a. No
b. Yes
c. n/a
No.
Reports
lifetime
risk of
over-
diagnosis* 1.8 to 6%*
Other
sensitivity
analyses
performed. Moderate
Heijnsdijk
200955;
Prostate;
MISCAN
Europe;
55-70 every 1 or 2
years or 55-75
every 4 years
a,b. ERSPC Rotterdam
c. Cure rates by stage from
Amsterdam Cancer Center
a. No
b. Yes
c. n/a
Yes
(estimated
from
figures)
Annual: 60%
Biennial: 60%
Every 4 years (to age
75): 67% Not performed High
McGregor
199856;
Prostate
Quebec, 50-85;
Annual PSA 50-70
a. see appendix table
b. Quebec Ministry of Health
a. No
b. Yes
c. n/a Yes 84%
Other
sensitivity
analyses
performed. High
Pashayan 200957;
Prostate
UK;
Single PSA
a. Eastern Cancer Registry,
ProtecT study, UK Office
of National Statistics
b. UK Office of National
Stats
a. No
b. Yes
c. n/a Yes
50-4: 10% (7-11)
55-9: 15% (12-15)
60-4: 23% (20-24)
65-9: 31% (26-32) Not performed High
Telesca 200858;
Prostate
US;
Typical US
screening patterns
a. SEER 1973-87
b. CDC Vital Statistics 1992
a. No
b. Yes
c. n/a Yes
White men: 22.7%
Black men: 34.4% Not performed High
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Study;
Cancer type;
Model(s)
Modeled
population:
Country, ages;
Screening
schedule
Data Sources
a. Incidence
b. Mortality
c. Other
a. External
Validation?
b. Includes
Competing
Mortality?
c. Includes
DCIS?
Reports
Preferred
Outcome?
Magnitude of
Overdiagnosis
(95% CI)
Sensitivity
Analyses
varying mean
sojourn time
or lead time?
Overall
Risk of
Bias
Tsodikov 200659;
Prostate
US;
Typical US
screening patterns
a. SEER
b. Human Mortality Database
a. No
b. Yes
c. n/a Yes 30% Not performed High
Wu 201260;
Prostate
Finland,  55, 59,
63, 67;
3 PSA tests every 4
years until 71
a. Finnish Prostate Cancer
Screening Trial, Finnish
Cancer Registry
b. Statistics Finland
a. No
b. Yes
c. n/a No*
3.4% (2.4-5.7) risk of
overdetection during
study period* Not performed High
De Gelder 2011
(Epi Rev)61;
Breast;
MISCAN
Netherlands, 0-
100;
Biennial mammo
49-74
a. Dutch Comprehensive
Cancer Centers, National
Evaluation Team for
Breast Cancer Screening
1990-2006
a. No
b. Yes
c. Yes Yes
Implementation: 22.1-
67.4%
Extension: 15.4-30.5%
Steady state: 8.9-15.2% Not performed High
De Gelder 2011
(Prev Med)62;
Breast;
MISCAN
Netherlands, 0-
100;
Biennial screen
film or digital
mammo
a. Dutch Cancer Registry,
National Evaluation Team
for Breast Cancer
Screening 1990-2006
a. No
b. Yes
c. Yes Yes
Screen film: 7.2%
Digital: 8.2%
Other
sensitivity
analyses
performed. High
Duffy 200549;
Breast
Sweden, 40-74/ 39-
59;
Mammo every 18,
24 or 33 months
All Data: Swedish 2-County
RCT (1977-84) and
Gothenburg RCT (1982-87)
(separate analyses)
a. No
b. No
c. Yes Yes
Swedish: 1st screen
3.1% (0.1-10.9), 2nd:
0.3% (0.1-1), 3rd: 0.3%
(0.1-1).
Gothenburg: 1st: 4.2%
(0.0-28.8), 2nd: 0.3%
(0.0-2.0), 3rd: 0.3%
(0.0-2.0) Not performed High
Gunsoy 201263;
Breast
UK, 40-49;
Annual mammo
a. England/Wales Office of
National Statistics, Age
RCT Control Arm
b. Office of National
Statistics
c. Parameter estimation
model: Age RCT
a. No
b. Yes
c. Yes Yes 0.70%
Univariate.
Varied MST
and sensitivity.
0.5 to 2.9% Moderate
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Study;
Cancer type;
Model(s)
Modeled
population:
Country, ages;
Screening
schedule
Data Sources
a. Incidence
b. Mortality
c. Other
a. External
Validation?
b. Includes
Competing
Mortality?
c. Includes
DCIS?
Reports
Preferred
Outcome?
Magnitude of
Overdiagnosis
(95% CI)
Sensitivity
Analyses
varying mean
sojourn time
or lead time?
Overall
Risk of
Bias
Martinez-Alonso
201052;
Breast
Spain, 25-84;
Biennial mammo
50-69
a. Girona Cancer Registry
and IARC Registry
a. No
b. Yes
c. No
No.
Reported
as percent
excess of
expected
incidence.
*
1935 birth cohort:
0.4% (-8.8 to 12.2)
1940: 23.3% (9.1-
43.4%)
1945: 30.6% (12.7-
57.6%)
1950: 46.6% (22.7-
85.2%)*
Univariate.
Varied MST
from 1 to 5.
18.3 to 51.1% Moderate
Olsen 200650;
Breast
Denmark, 50-69;
Biennial mammo
50-69
a. Danish Cancer Registry,
Breast Cancer Cooperative
Group, Central Population
Registry
a. No
b. No
c. Yes Yes
1st screen 7.8% (0.3-
27.5)
2nd screen: 0.5% (0.01-
2.2%)
Other
sensitivity
analyses
performed High
Seigneurin
201251;
Breast
France, 50-69;
Not specified
a. French population-based
study by Seigneurin 2009
a. No
b. No
c. Yes Yes
DCIS: 31.9% (2.9-62.3)
Invasive cancer: 3.3%
(0.7-6.5)
Univariate.
Varied MST.
DCIS: 17.3-
51.7%
Invasive: 0-
8.9% Moderate
Hazelton 201264;
Lung
Heavy smokers,
<5yrs asbestos
exposure;
Low dose CT
a,b. CARET (calibration)
c. Calibrated model applied
to NYU Biomarker Center
Trial and Moffitt Cancer
Center Trial
a. No
b. Yes
c. n/a Yes
Men: 14.1% (11.6-19.7)
Women: 35.2% (28.9-
39.3) Not performed High
Pinsky 200465;
Lung
Men 50-75, heavy
smokers;
Annual CXR and
sputum cytology
50-75
All data: Mayo Lung
Screening Trial (prevalence
screen and screening arm
only)
a. No
b. Yes
c. n/a Yes 13 to 17% Not performed High
Luo 201266;
Colon
Cohort age 40, 50
or 60;
5 annual or 3
biennial FOBT
a. Minnesota Colon Cancer
Control study (1976-82)
b. SSA life tables
a. No
b. Yes
c. n/a
Yes
(reported
for age
50)
Females: 6.65% (2.56-
20.49)
Males: 6.15% (1.92-
44.69%) Not performed High
Abbreviations: MST, mean sojourn time; FHCRC, Fred Hutchinson Cancer Research Center; mammo, mammography; IARC, International Registry for Research on Cancer;
CARET, Carotene and Retinol Efficacy Trial; MLT, Mayo Lung Trial
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Risk of Bias: Modeling Studies
For this review, we developed new criteria for evaluating risk of bias of modeling studies.  An
ideal modeling study would clearly state its assumptions and data sources in a table, and all assumptions
would be supported by evidence identified and quality rated in a systematic review.  Only one modeling
study48 provided a table of assumptions, and none were supported by systematically-reviewed evidence.
Instead, most studies picked different data inputs from a variety of sources without justification for the
use of such diverse sources.  This raises the risk of manipulation of the model to achieve a desired output
and thus the risk for bias.  An alternative to performing a systematic review to inform the model with high
quality evidence would be to use all data inputs from a well-done randomized controlled trial.  One breast
cancer modeling study49 did use all data from the Swedish 2-County and Gothenburg randomized
controlled trials and was given credit for its use of consistent unbiased data sources, but this study had a
fatal flaw in that it did not perform sensitivity analyses.  Three other studies55,63,66 used some data from a
randomized controlled trial but also pulled data from other sources.
We also attempted to rate modeling studies on the probability for biases in the data used in the
model.  We expected that authors would choose data sources in an attempt to minimize bias as well as
discuss the potential biases in their choices in an effort to convince the reader of the validity of their
results.  However, none of the modeling studies provided any information or discussion on potential
biases in their data.
A major component of the risk of bias assessment for modeling studies was the performance of
sensitivity analyses.  The ideal study would perform probabilistic multivariate sensitivity analyses for key
uncertain parameters including mean sojourn time or lead time.  Only four studies specifically varied
mean sojourn time in univariate sensitivity analyses51-53,63 and one other study varied rates of disease
onset, metastasis and clinical detection,48 which is likely equivalent.  All other studies either performed
minimal sensitivity analyses that did not directly address key uncertain variables or did not perform
sensitivity analyses at all, both of which we considered fatal flaws with high risk of bias.
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Several studies used a data set to calibrate the model and determine uncertain model parameters,
such as transition probabilities between different states in the model, and then “validated” the model by
fitting it to the same original data set. A study which truly externally validated its model would use one
data set to calibrate the model and determine parameters and then externally validate it to another data set
in a different population. Performing this external validation would lend more credibility to the
assumptions made in the model and would make it more likely that the calibrated parameters are
applicable to more than just the modeled population. None of the modeling studies included in this
review performed external validation of their models and thus did not achieve this degree of credibility.
We rated the majority of modeling studies as having a high risk of bias because they had a fatal
flaw of not performing sensitivity analyses for key uncertain variables, in addition to the other potential
biases already discussed.  The five studies that performed univariate sensitivity analyses as described
above were rated as having moderate risk of bias, as none performed external validation or informed the
model with systematically reviewed evidence or data from a single randomized trial.
Strength of Evidence: Modeling Studies
We assessed strength of evidence for modeling studies grouped by cancer type, with other criteria
in addition to risk of bias being directness, external validity, precision and consistency. Our ratings for
each study are available in Appendix Table 3. Directness for all modeling studies was rated as poor,
because by nature the models used to draw conclusions about overdiagnosis require assumptions about
progression of cancer from early, preclinical stages to later stages.  The nature of this progression is
fundamental to the question of overdiagnosis and its magnitude, so in many ways it is inappropriate that
models attempting to answer such questions would require such assumptions.  Ratings for external
validity for prostate cancer modeling studies were generally good, as these studies tended to be based on
US data and based on typical US screening patterns.  In contrast, all the breast cancer models were based
on European populations and screening situations, which differ from the US in having a much lower
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diagnostic rate of DCIS, and thus were rated as fair for external validity. We were often unable to
determine the precision of the overdiagnosis estimates because confidence intervals were not provided in
many cases, but in most other cases precision was fair to poor.  Finally, we rated consistency for both
breast and prostate cancer modeling studies as poor. Strength of evidence was rated as low for breast,
prostate, lung and colon cancer modeling studies.
Characteristics of Included Studies: Pathologic and Imaging Studies
We included eight studies that drew conclusions about overdiagnosis based on a pathologic or
imaging characteristics, six of lung cancer overdiagnosis and two of prostate cancer overdiagnosis. Table
3 highlights the characteristics of these included studies, and full details are available in Appendix Table
4. The lung cancer studies were typically small studies that retrospectively looked at volume doubling
time of patients diagnosed with lung cancer by screening chest x-ray or CT scan.  These studies included
a total of 376 cancers.  The definition for overdiagnosis was typically set at a volume doubling time of
400 days, though one study used 300 days67, and one study used information on volume doubling time to
calculate the patient’s expected time of death which was then compared with the typical life expectancy in
Japan to determine if the cancer was overdiagnosed.68 Another study with unique methods among those
of lung cancer followed patients diagnosed with screen-detected clinical stage 1 lung cancer who did not
undergo surgical treatment and defined overdiagnosis as death from a cause other than lung cancer.69
Estimates of lung cancer overdiagnosis varied from “minimal” to 27% in these studies.
The two pathologic/imaging prostate cancer studies involved a total of 3093 patients and used
similar definitions of overdiagnosis based on Gleason score, negative surgical margins and other
criteria.41,70 Patients in both studies were undergoing radical retro-pubic prostatectomy for prostate cancer
detected in various screening situations.  Estimates of overdiagnosis were 4.5%70 and 16.8%41.
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Table 3: Summary Evidence Table of Pathologic and Imaging Studies
Study
Cancer Type
Study Period
Country
# of cancers
Screening test Overdiagnosis Definition Results
Magnitude of
Overdiagnosis
(95% CI)
Overall
Risk of
Bias
Dominioni 201267
Lung
1997-2011
Italy
21
CXR VDT> 300 days 1/21 cancers had VDT > 300 days “minimal” Moderate
Lindell 200771
Lung
1999-2004
US
61
CT VDT>400 days 13/48 cancers had VDT>400 days 27% Moderate
Sobue 199269
Lung
1976-1989
Japan
42
CXR
Dying from a cause other than
lung cancer in patients diagnosed
with clinical stage 1 disease
20% of screen-detected patients died
from cause other than lung cancer “minimal” High
Sone 200768
Lung
1996-1998
Japan
45
CT
Expected age of death (calculated
from VDT) greater than average
Japanese life expectancy
6 of 45 cases had expected death age
greater than Japan life expectancy 13.3% High
Veronesi 201272
Lung
2004-2010
Italy
120
LDCT VDT>400 days 31/120 cases had VDT> 400 days
25.8% (18.3-
34.6) Moderate
Yankelevitz
200373
Lung
Not provided
US
87
CXR/sputum
cytology VDT> 400 days 4/87 cases had VDT> 400 days 5% High
Graif 200770
Prostate
1989-2005
US
2126
PSA
tumor volume <0.5 cm3, Gleason
<7, organ-confined disease in RRP
specimen with clear surgical
margins
4.5% met criteria for overdiagnosis
compared with 27% meeting criteria
for underdiagnosis 4.5% High
Pelzer 200841
Prostate
1999-2006
Austria
997 (806
screened, 161
unscreened)
PSA
Gleason <7, pathologic stage of
pT2a and negative surgical
margins
16.8% of screened group and 7.9% of
unscreened met overdiagnosis criteria 16.8% High
Abbreviations: CXR, chest x-ray; VDT, volume doubling time; CT, computed tomography; LDCT, low-dose computed tomography; RRP, radical
retropubic prostatectomy;
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Risk of Bias: Pathologic and Imaging Studies
As most pathologic and imaging studies did not have control groups, traditional selection bias and
confounding were not the key internal validity issues for these studies. However, many of the lung cancer
studies were unable to obtain complete follow-up information on their initial set of diagnosed cancers and
omitted certain patients from the analysis, increasing the risk for bias by arbitrarily cutting down an
already limited sample.  The Sobue et al 69 study, which followed patients with stage 1 lung cancer to
determine causes of death, compared screen-detected patients to a control group of patients with
symptom-detected lung cancer who were matched by age within 5 years, sex and year of diagnosis.  This
study had a high risk for selection bias and confounding because it did nothing to mitigate confounding
beyond matching, in addition to having low numbers and omitting several patients from the analysis.
Likewise, the Pelzer 2008 et al41 study of prostate cancer compared overdiagnosis based on RRP
specimens from a screened group compared to an unscreened referred cohort without controlling for any
confounders.  In a similar study, Graif and colleagues created a study group of “screened” individuals
based on three different sets of screening and biopsy criteria.70
While many studies had problems with incomplete data, selection bias, and confounding,
measurement bias was the major flaw in many of these pathologic and imaging studies.  In the Sobue et al
study of lung cancer, verification of the cause of death was not convincingly valid and reliable as only 35
of 42 patients who died of lung cancer even had progression of their lung cancer verified in their medical
records.69 Yankelevitz et al73 calculated volume doubling time for lung cancers with data obtained from
two different studies.  For one study, individual data on tumor size was available, but for the other study
only the frequency distribution of tumor dimension and disease stage at the time of diagnosis was
available without data on individual tumor size, so the authors assumed the smallest tumors were the
stage 1 malignancies.  We rated these two studies as having a high risk of measurement bias. The Graif et
al study of prostate cancer also had a high risk for measurement bias as different procedures were used
during the study to determine tumor volume.70 The other lung cancer studies were rated as moderate risk
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of measurement bias because they provided minimal information on how volume doubling time was
calculated and whether it was done in a valid and reliable way. Likewise, the final prostate cancer study
provided minimal information on the uniformity of the RRP procedures producing the study specimens
and had only one pathologist reading biopsies.41
Overall, three lung cancer studies had a high risk of bias68,69,73, and three had a moderate risk of
bias.67,71,72 Both prostate cancers studies had a high risk of bias.41,70
Strength of Evidence: Pathologic and Imaging Studies
Ratings for Risk of Bias and Strength of Evidence criteria for pathologic and imaging studies are
available in Appendix Table 5. Directness was poor for all pathologic and imaging studies, with one
exception, because the validity of the conclusions of the studies was contingent on the assumption that the
pathologic or imaging characteristics were directly correlated with cancer-related morbidity and mortality.
With the exception of Veronesi and colleagues72, no authors attempted to explain the linkage between the
pathologic or imaging characteristic and cancer progression or to justify the somewhat arbitrary cutoff
they had chosen as the definition of overdiagnosis. In contrast, directness was good for the Sobue et al
study69 because this study followed untreated early stage cancer patients until death from cancer or
another cause, directly examining the link between cancer diagnosis and cancer death.  Unfortunately, the
study’s methodologic flaws limit its usefulness.  External validity was fair for the majority of studies
either due to European settings or to use of screening tests such as chest x-ray that are no longer relevant
to current screening discussions.  Authors mostly did not provide confidence intervals for overdiagnosis
estimates so we were unable to determine precision.  Based on a moderate to high aggregate risk of bias
along with poor directness, fair external validity, questionable precision and lack of consistency, we rated
the strength of evidence as low for both prostate and lung cancer pathologic and imaging studies.
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Characteristics of Included Studies: Ecologic and Cohort Studies
A total of 21 ecologic and cohort studies were included in this review, the full details of which
are available in Appendix Table 6.  Table 4 provides the summary details of 19 of these studies, 17 of
breast and two of prostate cancer overdiagnosis.  Two additional prostate cancer cohort studies74,75 are not
included in the summary table because they do not share many of the relevant issues, but these studies are
listed in the full appendix table. Of the breast cancer studies, one took place in the United States30 and
one in New South Wales, Australia76, with the rest being performed in European countries.  The majority
of these studies were ecologic studies in European countries, but several were cohort studies that took
advantage of population-based registries to track large numbers of individuals for their screening
experiences and cancer outcomes.  The screening programs were fairly comparable between studies,
tending to involve biennial mammography most commonly for women ages 50 to 69 years. One study
looked only at younger women ages 40 to 49 years77, and a few included some screening extended to
women in their seventies.78,79
The breast cancer studies used several variations of unscreened reference populations in
comparison with the screened populations studied.  Most studies modeled the continuation of the pre-
screening period incidence trend throughout the screening period with linear regression as the reference.
A few studies77,80,81 took advantage of the fact that screening programs were introduced gradually
throughout certain countries and were able to use contemporary counties where screening had not yet
been introduced as the reference population.  One study used historical age-matched cohorts as the
reference.79 Another two studies used a combination of three control groups, including a contemporary
unscreened group and historical groups in the regions with and without screening, in an effort to control
for differences in baseline incidence trends between geographic areas.82,83 Finally, two studies compared
screening program attenders to non-attenders as the reference group.46,84 The magnitude of overdiagnosis
reported in breast cancer ecologic and cohort studies was highly variable and ranged from 1% to 76%,
depending on age group and the way overdiagnosis was calculated.
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Table 4: Summary Evidence Table of Ecologic and Cohort Studies
Study
Cancer Type
Study
Design
Study
Population:
Country
Ages
Time Period
Reference
Population
Adjustment for
Confounders
Management
of Lead Time
Calculation of
Overdiagnosis
Magnitude of
Overdiagnosis
(95% CI)
**does not include DCIS
A.Risk of
Bias
B. Timeframe
C.Analysis
Bleyer 201230
Breast
Ecologic
US
40+
1976-2008
Pre-screening
trend (1976-8)
HRT, baseline
increasing
incidence
Steady-state
screening
(excess cases)/
(observed cases)
during screening 31%
A.Moderate
B. Good
C. Good
Duffy 201078
Breast
Cohort and
Ecologic
Sweden
50-60
1977-98;
UK
47-73
1989-2003
Calculated from
Swedish 2-
County control;
UK: Pre-
screening trend
(1974-89)
Swedish:
Unclear
UK: Baseline
changes in
incidence
Swedish:
excluded
prevalence
screen
UK: unclear
Based on complex
calculation
Swedish: 12%¥
UK: 2.3 per 1000
screened for 20 years
A.Moderate
B. NA
C. Poor
Falk 201384
Breast
Cohort
Norway
50-69
1995-2009
Screening
program non-
attenders
Age, county,
calendar year
10-year FU
post-screening
(excess cases)/
(expected cases)
during screening 19.4% (11.8-27.0)
A. High
B. Good
C. Good
Hellquist
201277, breast
Ecologic
Sweden
40-49
1986-2005
Contemporary
counties w/o
screening
Differences in
baseline
incidence trends
Statistical
adjustment
(excess cases)/
(expected cases)
during screening
1% (-6 to 8%)
[16% w/o lead time
adjustment]
A.Moderate
B. NA
C. Poor
Jorgensen
2009 (BMJ)85
Breast
Ecologic
UK: 50-64
(1993-1999)
CA:50-69 (1995-
2005)
NSW: 50-69
(1996-2002)
Sweden: 50-69
(1998-2006)
Norway:50-69
(2000-2006)
Pre-screening
trend (UK 1971-
84, CA 1970-78,
NSW 1972-87,
Sweden 1971-85,
Norway 1980-
94)
Baseline
increasing
incidence
Up to 7-year
FU post-
screening
(excess cases)/
(expected cases)
during screening
UK: 57% (53-61%)
CA: 44% (25-65%)
NSW: 53% (44-
63%)
Sweden: 46% (40-
52%)
Norway: 52% (36-
70%)
Meta-analysis: 52%
(46-58%)
A.Moderate
B. Fair
C. Good
Jorgensen
2009(BMC)80
Breast
Ecologic
Denmark
50-69
1991-2003
Contemporary
counties w/o
screening
Age and
differences in
baseline
incidence trends
Up to 10-12
years FU post-
screening
(excess cases)/
(expected cases)
during screening 33%
A.Moderate
B. Fair
C. Good
Junod 201179
Breast
Ecologic
France
50-79
1995-2005
Age-matched
historical cohorts
from 1980-90
HRT, alcohol
and obesity Unclear
excess cases)/
(expected cases)
during screening
Ages 50-64: 76%
(67-85%) **
Ages 65-79: 23%
(15-31%) **
A.Moderate
B. Fair
C. Poor
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Study
Cancer Type
Study
Design
Study
Population:
Country
Ages
Time Period
Reference
Population
Adjustment for
Confounders
Management
of Lead Time
Calculation of
Overdiagnosis
Magnitude of
Overdiagnosis
(95% CI)
**does not include DCIS
A.Risk of
Bias
B. Timeframe
C.Analysis
Kalager
201283
Breast
Ecologic
Norway
50-79
1996-2005
Contemporary
counties w/o
screening, and
historical cohorts
in screening
region and w/o
screening
Differences in
baseline
incidence trends
Including
women up to
79  in
incidence, w/
up to 10 years
FU post-
screening
(excess cases)/
(observed cases)
during screening period,
including women up to
age 79
Entire country: 25%
(19-31%) **
County w/10yrs
follow-up: 18% (11-
24%) **
A.Moderate
B. Fair
C. Poor
Morrell
201076, breast
Ecologic
NSW, Aust.
50-69
1991-2001
Pre-screening
trend (1972-90)
HRT, obesity,
and nulliparity
Statistical
adjustment
(excess cases)/
(expected cases)
during screening 30% **
A.Moderate
B. NA
C. Poor
Njor 201382
Breast
Cohort
Denmark
(Copenhagen
/Funen)
56-79/59-78
1991/93-2009
Contemporary
counties w/o
screening, and
historical cohorts
in screening
region and w/o
screening
Differences in
baseline
incidence trends
Up to 8 years
follow-up
post-screening
(excess cases)/
(expected cases)
during screening and 8-
years post-screening
Copenhagen: 6% (-
10 to 25%)
Funen: 1% (-7 to
10%)
Pooled: 2.3% (-3 to
8%)
A.Moderate
B. Fair
C. Poor
Paci 200686
Breast
Cohort
Italy
50-74
1986-2006 (10-
year period)
Pre-screening
trend Age
Statistical
adjustment
(excess cases)/
(expected cases)
during screening
4.6% (2-7%) after
adjustment for lead
time
36.2% (34-39%)
before adjustment
for lead time
A.Moderate
B. NA
C. Poor
Peeters
198981
Breast
Ecologic
Netherlands
35+
1975-86
Contemporary
county w/o
screening None Did not
(excess cases)/
(expected cases)
during screening 11%
A.High
B. Poor
C. Poor
Puliti 200945
Breast
Cohort
Italy
60-69
1990-2005
Pre-screening
trend (forced to
1.2% growth) Age
5-10 years FU
post-screening
(excess cases)/
(expected cases)
during screening and 5-
years post-screening 1% (-5 to 7%)
A.Moderate
B. Fair
C. Poor
Puliti 201246
Breast
Cohort
Italy
60-69
1991-2007
Screening non-
attenders
Age, marital
status, and area-
level socio-
economic status
5-14 years FU
post-screening
(excess cases)/
(expected cases)
during screening and 5-
14 years post-screening 10% (-2 to 23%)
A.High
B. Fair
C. Poor
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Study
Cancer Type
Study
Design
Study
Population:
Country
Ages
Time Period
Reference
Population
Adjustment for
Confounders
Management
of Lead Time
Calculation of
Overdiagnosis
Magnitude of
Overdiagnosis
(95% CI)
**does not include DCIS
A.Risk of
Bias
B. Timeframe
C.Analysis
Svendsen
200687
Breast
Ecologic
Denmark
50-69
1991-2001
Pre-screening
trend (1979-90) Age Did not Not calculated
“None” (See
appendix table) **
A.Moderate
B. Poor
C. Poor
Zahl 200488
Breast
Ecologic
Norway (N)
50-74
1995-2000
Sweden (S)
50-70
1986-2000
N: Pre-screening
period (1991)
S: Pre-screening
trend (1971-85) Age
Up to 4 (N)
and 14 (S)
years FU post-
screening
(excess cases)/
(expected cases)
during screening
N: 56% (42-73%)
increased incidence
with no post-
screening drop **
S: 45% (41-49%)
increased incidence
with 12% drop **
A.Moderate
B. Poor (N)/
Fair (S)
C. Good
Zahl 201289
Breast
Ecologic
Norway
50-79
1995-2009
Pre-screening
trend (1991-5)
Age, county,
population
growth and
baseline
incidence trend
Up to 14 years
FU post-
screening
(excess cases)/
(expected cases)
during screening
Confirmed 50%
incidence growth
from Zahl 2004, with
non-significant drop
of 7% in women 70-
74
A.Moderate
B. Fair
C. Good
Ciatto 200590
Prostate
Cohort
Italy
60-74
1991-2000
Contemporary
counties w/o
screening Age
7-9 year FU
post-screening
(excess cases)/
(expected cases)
during screening and 9-
years post-screening 66% (40-100%)
A.Moderate
B. Fair
C. Poor
Zappa 199891
Prostate
Cohort/
Modeling
Italy
60 or 65
Not provided
Contemporary
counties w/o
screening None
4 years FU
post-screening
(excess cases)/
(expected cases)
during screening and 4-
years post-screening
age 60: 25% (19-
32%)
age 65: 65% (58-
73%)
A.Moderate
B. Fair
C. Poor
Abbreviations: HRT, hormone replacement therapy; FU, follow up; w/o, without; CA, Canada; NSW, New South Wales;
¥Unclear if Duffy 2010 estimates of overdiagnosis include DCIS
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The prostate cancer studies included in the summary table were both set in Italy and were based
on different variations of a PSA screening schedule.  Both studies used contemporary unscreened counties
as the reference populations. The magnitude of overdiagnosis reported in these studies ranged from 25 to
66%, depending on age and method of calculation.90,91
Risk of Bias: Ecologic and Cohort Studies
Ecologic and cohort studies have an elevated risk for selection bias and confounding due to the
comparison of non-randomized populations or cohorts.  By choosing a control group that is as similar as
possible to the study group in factors associated with incidence of cancer, a study has the best chance of
minimizing the biases of confounding.  However, all potential reference populations that were used in the
included breast cancer ecologic and cohort studies, as discussed above, are problematic in certain ways.
Modeling the pre-screening incidence trend through the screening period requires the assumption that
incidence will continue growing at the same rate without any non-linear changes.  The use of
contemporary counties without screening programs as the reference population can introduce other
confounders that are distributed differently between the two geographic areas. The use of a historical
control group is complicated by confounders that have changed between time periods which are likely
substantial, but the study that did this adjusted for differences in breast cancer risk factors between eras,
thus moderating some of the bias.79 Studies that used three control groups82,83 as described above are
better able to account for differences in incidence growth between regions but still could be biased by
differential influence of confounders between regions.
We rated studies that used these various types of reference populations as having a moderate risk
of selection bias and confounding. Within this group of moderately-rated studies, some had a higher risk
for selection bias and confounding than others, and some studies took certain actions that increased their
credibility.  Three studies adjusted for breast cancer risk factors on a population level including hormone
replacement therapy use, nulliparity and obesity.30,76,79 In addition to performing an adjustment for
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hormone therapy use, Bleyer and Welch considered two “extreme” scenarios where incidence growth was
much greater than the rate predicted based on the pre-screening trend and were able to demonstrate
substantial overdiagnosis even given these extremes of incidence growth.30 It is helpful when authors
acknowledge and consider the uncertainties in their studies and perform analyses like these to
demonstrate a range of possible results. We rated two breast cancer cohort studies that compared
screening attenders and non-attenders46,84 as having a high risk of selection bias and confounding, because
non-attenders of health screenings and services are known to be much different from attenders in terms of
general health and other health behaviors. Finally, an early ecologic study by Peeters and colleagues was
rated as high risk for confounding because it used a contemporary county without screening as the
reference population without consideration for any confounders including age.81 Our ratings for risk of
bias for individual studies are available in Appendix Table 7.
Measurement bias was less of an issue for ecologic and cohort studies.  Most studies received a
rating of moderate risk of measurement bias because they did not discuss the validity and reliability of
their data sources, particularly for cancer incidence data.  Two studies did discuss the completeness and
accuracy of country registries with regards to cancer incidence data and screening information, when
relevant, and we rated these as low risk of measurement bias.83,84
We rated both the prostate cancer studies that were included in the summary table as having a
moderate risk of selection bias and confounding.  Both these studies90,91 used contemporary unscreened
regions of Italy as the reference population, without adjustment for confounders other than age. Neither
study discussed the validity and reliability of their data sources, thus we rated both as moderate risk of
measurement bias.
We rated the majority of the breast cancer ecologic and cohort studies as moderate in terms of
overall risk of bias, as most had a moderate risk of selection bias, confounding, and measurement bias.
Three breast cancer studies46,81,84 had a high risk of bias overall, due to a high risk of confounding and a
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moderate risk of measurement bias.  Both prostate cancer studies included in the summary table had a
moderate risk of bias overall.90
Strength of Evidence: Ecologic and Cohort Studies
In addition to risk of bias, ecologic and cohort studies were rated on analysis, directness, external
validity, precision, and consistency for an overall evaluation of strength of evidence within each cancer
type. Several analysis issues related to measuring and calculating overdiagnosis are unique to ecologic
and cohort studies.  The first is the appropriateness of the time frame over which overdiagnosis is
measured.  Related to this is the consideration of lead time, or the time that screening advances the
diagnosis of cancer in the screened group, such that the study population should be expected to have an
elevated incidence in comparison to the reference population over a certain time frame.  Studies need to
appropriately consider the lead time in their analysis or they risk under- or over-estimating overdiagnosis.
Finally, details of the overdiagnosis calculation itself, including the timeframe over which overdiagnosis
is calculated and who is included in the calculation, can affect the overdiagnosis magnitude and thus
should be performed in the most appropriate way.
Screening advances the time of diagnosis of preclinical cancers by a period of time known as the
lead time.  Because of this, cancer incidence is predictably increased in the screened study population
during the screening period because cancers that would have presented clinically during and after the
screening period are detected earlier by screening.  After the screening period, in the absence of
overdiagnosis, these cancers that would have presented clinically have already been detected by
screening, so incidence decreases in women in the post-screening period.  The duration of the drop in
incidence should equal the lead time, though typically there is a distribution of lead times that is largely
uncertain. Overdiagnosis in cohort and ecologic studies is typically investigated by looking for an
increase in incidence during screening in a screened population and a subsequent decrease in incidence in
the post-screening years, in comparison to a reference population that remains unscreened. Often,
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overdiagnosis is calculated by determining the excess cases of cancer in the screening group during the
screening period that are not balanced out by a deficit of cases in post-screening women. Studies that
obtain follow-up data for only a few years after screening ends may not sufficiently capture the post-
screening drop in incidence, often referred to as the “compensatory drop”, and thus can overestimate
overdiagnosis.  Some studies avoid the need for waiting for this extra follow-up by performing a
statistical adjustment for lead time, though we will discuss the downsides to this type of adjustment.
We rated the adequacy of the time frame of studies as one component of the analysis
considerations. Time frames were rated as good, fair or poor. Because the lead time and lead time
distributions of cancers are largely unknown and thus the true time needed for follow-up in these studies
is unknown, these ratings were used as a general guide to highlight where overestimation of overdiagnosis
might be occurring. When studies performed a statistical adjustment for lead time76-78,86 we did not rate
their time frame. Two studies did not have any follow-up of women post-screening and these were rated
as having a poor time-frame for evaluating overdiagnosis, 81,87 though both of these studies reported low
estimates of overdiagnosis that were thus not likely overestimates, and both also had other methodologic
flaws. A cohort study by Falk and colleagues84 achieved at least ten years of follow-up for all women in
the study post-screening, which we rated as a good time frame for evaluating overdiagnosis.  Another
study by Bleyer and Welch30 did not look at the overall incidence deficit in post-screening women but
rather the deficit of late-stage cases, and we rated this study’s time frame as good because it was
performed over a 30-year period during which screening had reached a steady-state.  The remaining
breast and prostate cancer ecologic and cohort studies achieved variable amounts of follow-up time post-
screening, from four years of complete follow-up on all study participants to up to fourteen years of
follow-up on the oldest subset of study participants. Many studies fulfilled a long amount of follow-up
time such that a post-screening drop could reasonably be expected to be completely seen in its oldest age
groups, but younger age groups were still undergoing screening or had only completed a few years of
post-screening follow-up.  We rated these studies as having a fair time frame.
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As mentioned previously, several studies performed a statistical adjustment for lead time as an
alternative to following up study participants in the post-screening period.  Conceptually, performing the
adjustment for lead time in its simplest form is equivalent to adding “n” years, where “n” equals the lead
time, to the age of each woman in the screening group at the time of a cancer diagnosis.  Women in the
screening group with this age adjustment are then compared with women in the control group for the
assessment of overdiagnosis.  Performing this type of adjustment for lead time introduces a high degree of
uncertainty into the analysis because the mean lead time is largely unknown, and because there is likely a
wide distribution of lead times such that this type of simple adjustment is a gross over-simplification.
Because of this, we rated the analysis of studies that performed a statistical adjustment for lead time as
poor.76-78,86
There are many complexities to the calculation of overdiagnosis, and we listed how the
overdiagnosis estimate was calculated for each study in the Summary Evidence Table 4.  Much of the
discussion in past reviews on overdiagnosis has revolved around the denominator for the overdiagnosis
calculation61, and we agree that the choice of denominator can greatly influence the magnitude of
overdiagnosis that is reported.  Study authors differ on what choice of denominator they think is most
appropriate, and sometimes estimates can only be presented in certain ways due to the types of data that
are available. Because an overdiagnosed cancer can only be one that was diagnosed by screening and not
an interval cased diagnosed by symptoms or a case diagnosed outside of a screening period, we believe
that overdiagnosis should be reported as the excess cases divided by the total screening-detected cases.
None of the included ecologic and cohort studies reported overdiagnosis in this way, however. The
majority of studies reported overdiagnosis as the percentage of cases expected in the absence of
screening, which was determined from the reference population.  Two studies reported overdiagnosis as
the percentage of cases that were observed in the screening group.30,83 We felt that the use of any of these
denominators could be appropriate and justifiable as long as the calculation was clearly explained.
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Because only cancer cases that are diagnosed by screening, and thus during the screening period,
can be overdiagnosed, it is only appropriate for overdiagnosis to be calculated over the screening period
and not over a screening period and an extended period of follow-up.  Many ecologic and cohort studies
have provided an estimate of overdiagnosis as the risk ratio of the cumulative incidence of cancer in the
screening group compared to the reference group over a period of follow-up after the screening period.
The following example illustrates why this analysis is problematic.
Table 5:  Overdiagnosis Analysis Example 1
(A) Reference
Population
(B) Screening
Population
(No Overdiagnosis)
(C) Screening
Population (with
Overdiagnosis)
Year Cancer Incidence Cancer Incidence Cancer Incidence
2000-2004 (screening period) 30 per 1000 60 per 1000 60 per 1000
2005-2009 (post-screening period) 40 per 1000 10 per 1000 30 per 1000
Using the information from the table above, when comparing the reference population (A) to the
screening population (B) which does not have overdiagnosis, overdiagnosis can be calculated in two
ways.  First, overdiagnosis can be calculated as the ratio of the cumulative incidences in the screening and
reference populations over the combined screening and post-screening periods, (70/1000)/(70/1000)=
1.00 or 0% overdiagnosis.  Second, overdiagnosis can be calculated as the excess cases diagnosed in the
screening period that are not compensated for by a deficit of cases in the post-screening period, divided
by the expected cases during the screening period, [60-(40-10))/1000]/[30/1000]= 1.00 or 0%
overdiagnosis. An equivalent way to think about this is the absolute excess of cases diagnosed in the
screened group over the entire screening and post-screening period, divided by the expected cases during
the screening period, or (70-70)/(30/1000)= 0% overdiagnosis. Although different denominators can be
used, and we would argue that screen-detected cases diagnosed during the screening period would be the
most appropriate denominator, the main point is that the time frame of the denominator should represent
the screening period and should not include any post-screening cases. In the case of comparing two
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populations where there is no overdiagnosis, the method of calculation is irrelevant and the resulting
overdiagnosis estimate is the same as demonstrated by these calculations.
However, when we compare the reference population (A) with a screened population (C) that
does have overdiagnosis present, the method of calculation becomes important. Performing the
calculation as the risk ratio of cumulative incidences over the combined screening and post-screening
periods yields (90/1000)/(70/1000)= 1.29 or 29% overdiagnosis.  Performing the analysis over just the
screening period, by calculating the excess cases not balanced by post-screening deficit cases, yields [(60-
(40-30))/1000]/(30/1000)= 1.67, or 67% overdiagnosis.  Equivalently, the absolute excess of cases in the
screened population (20), divided by the expected cases during the screening period (30), gives the same
percentage of overdiagnosis, 67%. It is inappropriate to calculate overdiagnosis using the first method, by
including cases diagnosed in the screening and post-screening periods, because cases diagnosed in the
post-screening period have no potential to be overdiagnosed.  The inclusion of these cases dilutes the
estimate of overdiagnosis.
Furthermore, the calculation of overdiagnosis by inclusion of cases diagnosed in the screening
and post-screening periods results in a measure that is highly dependent on the length of follow-up time,
as illustrated by the following example.
Table 6: Overdiagnosis Analysis Example 2
(A) Reference Population
(C) Screened Population
(with Overdiagnosis)
Year Cancer Incidence Cancer Incidence
2000-2004 (screening period) 30 per 1000 60 per 1000
2005-2009 (post-screening period) 40 per 1000 30 per 1000
2010-2014 (post-screening period) 40 per 1000 40 per 1000
First, calculating overdiagnosis as the ratio of cumulative incidences in the screened and reference
populations over the screening and five year post-screening periods yields (90/1000)/(70/1000)= 1.29 or
29% overdiagnosis.  Similarly, calculating overdiagnosis as the ratio of cumulative incidences over the
screening and ten year post-screening periods yields (130/1000)/(110/1000)= 1.18 or 18% overdiagnosis.
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However, if the analysis is restricted to the screening period, the overdiagnosis estimate remains stable
regardless of the amount of post-screening follow-up.  Calculating overdiagnosis as the excess cases in
the screening period not compensated by a deficit in the 5-year post-screening period, divided by
expected cases during screening, yields [(60-(40-30))/1000]/[30/1000]= 1.67 or 67% overdiagnosis.
Calculating overdiagnosis as the excess cases in the screening period not compensated by a deficit in the
10-year post-screening period, divided by expected cases during screening, yields [(60-(80-
70))/1000)]/[30/1000]= 1.67 or 67% overdiagnosis.  Using the second method of analysis, overdiagnosis
is not a function of the follow-up time, making this method much more appropriate for evaluating the true
extent of overdiagnosis and comparing results across studies.
Many of the breast and prostate cancer ecologic and cohort studies included in this review
calculated overdiagnosis as a risk ratio of cumulative incidences of the screened and reference
populations over the screening and follow-up periods.45,46,82,90,91 As discussed, this is inappropriate
because the overdiagnosis measure becomes a function of the length of follow-up time, and the cases
included in the calculation from the post-screening period dilute the true amount of overdiagnosis. Thus,
we rated the analysis of these studies as poor, because they all likely provided underestimates of
overdiagnosis.  Similarly, Kalager and colleagues included women up to age 79 in their calculation of
overdiagnosis as a ratio of cumulative incidences, even though screening was only offered to women
through age 69.83 This presents similar a problem of diluting the true amount of overdiagnosis because of
inclusion of cancer cases from women who could not have possibly been overdiagnosed, so we rated this
analysis as poor.  In another study by Junod and colleagues79, it was unclear if a post-screening period
was analyzed for a compensatory drop in incidence, or if lead time was managed in another way.  This
study possibly overestimated overdiagnosis, and we rated its analysis as poor. Finally, we rated the
analysis as poor of two remaining studies that did not have any follow-up of women post-screening.81,87
All other studies received good ratings for analysis because they limited their overdiagnosis calculations
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to the screening period and managed lead time by quantifying a deficit of incidence in post-screening
women80,84,85,88,89 or a deficit of late-stage disease.30
We rated directness for all ecologic and cohort studies.  Because none of these studies were able
to identify which individual women were overdiagnosed, and because these studies did not attempt to link
cancer diagnosis with cancer-related morbidity and mortality, we rated directness as fair for the majority
of studies.  For several studies that performed a statistical adjustment for lead time76-78,86, we rated
directness as poor, because these studies required an additional assumption about the progression of
cancer from preclinical to clinical stages.  External validity was fair for the vast majority of studies as
they were performed in European populations.  Two exceptions were the Bleyer and Welch study30 of
breast cancer overdiagnosis in the US which received a good rating, and the Hellquist et al study77 of
overdiagnosis in British women ages 40 to 49 which received a poor rating for the limited age group.
Precision was fair for the majority of studies, although many others did not provide confidence intervals.
Consistency was poor for both breast and prostate cancer overdiagnosis estimates.  Based on aggregate
risk of bias, analysis, directness, external validity, precision, and consistency, we rated the strength of
evidence as low for both breast cancer and prostate cancer ecologic and cohort studies. However, a few
breast cancer ecologic studies stood out among the body of evidence for providing a clearer view of the
magnitude of overdiagnosis, with a moderate risk of bias, an unbiased analysis, and fair time frames (with
the exception of Bleyer and Welch30, which had a good time frame).30,80,85,88,89
Characteristics of Included Studies:  Follow-Up of Randomized Controlled Trial
Only one study that met inclusion criteria measured overdiagnosis by following up a randomized
controlled trial.  This study was a 15-year follow-up of the Malmo randomized controlled trial of
mammography in Sweden, the characteristics of which are listed in Table 7. The full details of this trial
are listed in Appendix Table 8. In the original trial from 1976 to 1986, over 40,000 women ages 44 to 69
were randomized to either 5 to 6 rounds of mammography every 18 to 24 months or to no screening, and
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all women were subsequently followed for 15 years with the aid of Swedish population and cancer
registries. There was likely substantial contamination screening of the control group during the follow-up
period, as 24% of control participants underwent screening during the study period.  The reported
magnitude of overdiagnosis was 10% (95% CI 1% to 18%), which was calculated by including all cases
over the screening period and the fifteen years of follow-up.92 A letter to the editor by Welch and
colleagues noted that calculating overdiagnosis more appropriately over a denominator of cases detected
during the screening period leads to an overdiagnosis magnitude of 15%.  Welch goes further to calculate
our preferred outcome of overdiagnosis as a percentage of screen-detected cases in the Malmo trial and
found this to be 24%.93
Risk of Bias: Follow-Up of Randomized Controlled Trial
The follow-up of the Malmo randomized controlled trial was rated as having a low risk for
selection bias and confounding.  Although the details of the randomization procedures, allocation
concealment, baseline distribution of characteristics among groups, and attrition were not described in
either the original trial report94 or the overdiagnosis follow-up report92, a recent Cochrane review of
mammographic screening for breast cancer found these to be adequate with more extensive contact with
the authors.95 We rated the risk of measurement bias as moderate because the authors did not describe the
validity and reliability of their data sources, particularly over the fifteen-year follow-up period.92 Overall,
the study’s risk of bias was low.
Table 7: Summary Evidence Table of Randomized Controlled Trial Follow-Up Studies
Study;
Cancer
Type
Study Population:
Country, Age
Time Period
Post-
Study
Length of
Follow-Up
Calculation of
Overdiagnosis
Magnitude of
Overdiagnosis
(95% CI)
A.Risk of Bias
B. Time Frame
C.Analysis
Zackrisson
200692;
Breast
Sweden, 55-69
1976-1986 15 years
(excess cases)/
(control cases)
during trial and 15 years
follow-up 10% (1 to 18%)*
A.Low
B. Good
C. Poor¥
*Welch et al re-analysis93 found overdiagnosis of 15% as percentage of cases diagnosed during screening period;
overdiagnosis of 24% as percentage of screen-detected cases
¥Welch et al re-analysis rated as Good
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Strength of Evidence:  Follow-Up of Randomized Controlled Trial
Similarly to ecologic and cohort studies, we considered the analysis, directness, external validity,
and precision in the evaluation of strength of evidence. The ratings for all risk of bias and strength of
evidence criteria are listed in Appendix Table 9. We rated the time frame of this study as good because it
achieved complete 15-year follow-up of all women in the study, which is the most of any study included
in the review.  The analysis, however, received a poor rating, because overdiagnosis was calculated over
the entire fifteen-year follow-up period instead of over the screening period, which is problematic as
discussed previously in the ecologic and cohort study results section. The re-analysis performed by
Welch and colleagues received a good rating. Like ecologic and cohort studies, directness was fair, as
this type of study is unable to directly identify overdiagnosed cases.  External validity was also fair due to
the European population and time period. Precision was fair.  Based on a combination of these factors,
we rated overall strength of evidence for breast cancer randomized controlled trial follow-up studies as
moderate.
Discussion
Key Points
This review identified four major types of studies that have been used to measure overdiagnosis:
modeling studies, pathologic and imaging studies, ecologic and cohort studies, and follow-up of a
randomized controlled trial.  Using the frameworks for evaluating risk of bias and strength of evidence,
we identified strengths and weaknesses of each of these methods.
Modeling studies are not hindered by the constraints of time and are able to project through areas
of uncertainty.  However, sensitivity analyses from several of these studies demonstrated that varying key
uncertain variables like mean sojourn time or lead time could substantially change the overdiagnosis
estimate.  Furthermore, directness is poor for these studies as they require assumptions about the
progression of cancer from preclinical to clinical stages.  The majority of included studies made no efforts
45
to mitigate these uncertainties with unbiased selection of data sources, sensitivity analyses, or external
validation, and most had a high risk of bias.
Pathologic and imaging studies can be simple to perform and interpret but also are typically an
over-simplification of overdiagnosis, usually involving an arbitrary cutoff of a characteristic such as
volume doubling time to serve as the definition for overdiagnosis.  Directness is poor with these studies
as they require the assumption that the pathologic or imaging characteristic correlates with cancer
progression.  Furthermore, because these studies only deal with the non-progression aspect of
overdiagnosis and not the competing mortality component, they underestimate overdiagnosis and provide
a lower bound to estimates of it.
Ecologic and cohort studies can take advantage of the natural screening experiments taking place
in certain countries with gradual implementation of screening programs.  These studies must manage
confounders and often require a significant time commitment to adequately account for lead time by
following women through the post-screening period.  Randomized controlled trials have the advantage of
equally distributing confounders between study groups but probably entail an even longer time frame
between the study and follow-up period.
Comparison with Existing Literature
To our knowledge, there are no other existing systematic reviews that have comprehensively
identified all studies that measure overdiagnosis.  Several systematic and non-systematic reviews exist
that explore a subset of the overdiagnosis literature.  In 2012, the UK convened a panel of experts to
examine the benefits and harms of mammography and published their conclusions in a review.  This
review included a meta-analysis of overdiagnosis from the Malmo trial and the two Canadian trials of
mammography, where overdiagnosis was represented as a percentage of the total cases diagnosed during
the screening period and was found to be 19% overall.  They also performed a meta-analysis of
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overdiagnosis estimates expressed as a percentage of cases diagnosed over the entire follow-up period,
which we would argue is a flawed analysis that should not be considered.96
Biesheuvel and colleagues systematically reviewed studies of breast cancer overdiagnosis with a
focus on potential sources of bias in the estimates.  We agree that differences in risk profiles between
study groups, differences in participation in mammography, and inadequate consideration of lead time in
determining follow-up can affect overdiagnosis magnitude.  However, we disagree that statistical
adjustment and excluding prevalence screening data are appropriate ways to manage lead time.
Furthermore, Biesheuvel and colleagues advocate the “cumulative incidence method” for calculating
overdiagnosis which appears to be a major source of confusion for other researchers who have referenced
this review.  Using this method, overdiagnosis is calculated as the ratio of cumulative incidences in the
screened and unscreened groups at least several years after screening has ended, which is problematic and
dilutes the true amount of overdiagnosis as we have previously discussed.97 In another non-systematic
review, Moss discussed randomized controlled trials of mammography with a focus on overdiagnosis but
did not draw clear conclusions and also did not recognize the analysis flaw of including an extended
follow-up period.  Moss also attempted to calculate overdiagnosis for trials where screening was offered
to the control group at the end of the trial which was inappropriate.98 Puliti and colleagues reviewed
European observational studies of breast cancer overdiagnosis, making note of which studies they felt
adequately and did not adequately adjust for breast cancer risk and lead time.99 We disagree with their
assessment, as they favorably rated studies that statistically adjusted for lead time as well as studies that
included post-screening follow up years in the analysis.
Etzioni and colleagues non-systematically reviewed studies of breast and prostate cancer
overdiagnosis and discussed features of studies that influence the estimates of overdiagnosis including the
definition, measurement, study design, context, and estimation approaches.  They label ecologic and
cohort studies that do not statistically adjust for lead time as the “excess incidence approach” of
overdiagnosis estimation and argue that these studies may yield a biased estimate of overdiagnosis if the
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early years of screening dissemination are included.  They claim that the observed excess incidence is not
an unbiased estimate of overdiagnosis and provide a misleading example which seems to advocate
excluding the first few years of screening data to make an overdiagnosis estimate less biased.  We agree
that if a study includes only the first few years of screening dissemination without any post-screening
follow-up that this can be an overestimate of overdiagnosis, but very few of the existing ecologic and
cohort studies actually calculate overdiagnosis in this way.  Instead, most existing studies appropriately
measure incidence during the entire screening period and during a period of post-screening follow-up and
in so doing are able to accurately measure overdiagnosis provided that their post-screening follow-up is
sufficiently long.  Etzioni and colleagues have misrepresented the existing ecologic and cohort study
literature, and we disagree with their contention that ecologic and cohort studies that use the “excess
incidence approach” are inherently biased towards overestimation of overdiagnosis.100
Etzioni and colleagues also discuss modeling studies for measuring overdiagnosis which they
refer to as the “lead time approach”.  They point out that choices about the model structure and
assumptions can affect the overdiagnosis estimates, which we agree with.  However, they claim that the
main limitation of modeling studies is their lack of transparency, and that prior publication of the model
in peer-reviewed statistics literature is a positive indicator of the model’s validity.100 Rather than lack of
transparency, we believe that the inherent lack of directness of modeling studies and the ability of key
uncertain inputs to greatly affect overdiagnosis estimates are the primary limitations of modeling studies.
Prior model publication in the statistics literature is not a sufficient indicator of a model’s validity, and
authors of modeling studies should be encouraged to take steps to increase the validity of their study by
using systematically reviewed data inputs and performing sensitivity analyses and external validation.
Finally, Etzioni and colleagues point out a dichotomy in the selected studies they chose to
present, where modeling studies tended to have much lower estimates of overdiagnosis than ecologic
studies, particularly among breast cancer studies.100 Had they performed a systematic review, however,
they would have found several breast cancer modeling studies51,52,61 with much higher overdiagnosis
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estimates than the ones they chose to present, as well as ecologic studies45,46,82 with lower estimates than
those presented.  The suggestion by Etzioni that all ecologic and cohort studies overestimate
overdiagnosis is unfounded.
Limitations of the Literature
There are many barriers that make it challenging to perform a high quality study measuring
overdiagnosis.  Time is a major factor, as many countries that have the resources to perform these
ecologic or large-scale cohort studies have not established screening programs for long enough to draw
clear conclusions about overdiagnosis.  Many of the included studies had fair time frames for examining
overdiagnosis but had not adequately achieved follow-up to rule out overestimating overdiagnosis.
Maintaining a true reference population for ecologic and cohort studies is also a challenge.  More and
more people are being screened for cancer as technology spreads and awareness grows, limiting the
ability of researchers to make a direct comparison with an unscreened population.  The reference
population had contamination screening in many of the included studies.  In places like the United States,
researchers have to use modeling to determine expected incidence in the absence of screening because
there is no unscreened population available to examine.  Many other randomized controlled trials that
could have been followed for evaluation of overdiagnosis offered screening to the control group at the end
of the trial.  Management of confounding is always a challenge with ecologic and cohort studies.  Finally,
many of the available ecologic and cohort studies had analysis problems that limited the interpretability of
their results.  The primary limitations of the modeling and pathologic/imaging literature were the inherent
uncertainties and lack of directness of the studies.
Limitations of this Review
There were several limitations of our review.  Because of the large number of included studies,
we were unable to focus on the details of the individuals studies that were included.  Much of this
information should have been captured in the full evidence tables located in the appendices but was
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unable to be fully discussed.  We also combined certain studies when multiple studies were available
from the same authors or using the same model and population, and it is possible that we missed some of
the variability in the data available from these studies.  We limited the scope of our review to include only
the nine types of solid tumors with the highest incidence in US adults, so we may have missed some
studies on overdiagnosis that were performed on other types of cancer.  However, our search was not
limited to these cancer types and we did not come across any other overdiagnosis studies within another
cancer type during the abstract review process, with the exception of a few studies on neuroblastoma.
While we did our best to make our assessment of risk of bias and strength of evidence as rigorous and
objective as possible by using standard criteria, these ratings involved some subjectivity and it is possible
that different raters would have reviewed the evidence differently.
Implications for Future Practice and Research
Despite the major limitations of much of the overdiagnosis literature, there is an emerging picture
of a substantial amount of breast and prostate cancer overdiagnosis.  Several breast cancer ecologic
studies that had a moderate risk for bias with an adequate time frame and a sound analysis suggest that
overdiagnosis is above 30% of breast cancer cases expected in the absence of screening.30,80,85,88,89 The
few breast cancer modeling studies that looked at the typical screening age range and performed
sensitivity analyses also found overdiagnosis ranging from 20 to 50%, and both of these studies were
under-estimates because they did not model either DCIS or competing mortality.51,52 The prostate cancer
literature is more uncertain as there are many fewer ecologic and cohort studies, but the majority of
available studies suggest substantial overdiagnosis of prostate cancer as well.
The medical community needs to take action against overdiagnosis of cancer.  Steps that have
been suggested include raising the threshold for labeling a screening test result as abnormal, developing
new biomarkers that can distinguish between more indolent and aggressive cancers, changing medical
language to better reflect the benign nature of many of cancer diagnoses, and developing better education
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programs about overdiagnosis for physicians, residents, medical students and the public.  In some cases it
may be appropriate to re-evaluate decisions to screen or to offer screening altogether.  We also need to
begin a coordinated effort to monitor overdiagnosis in screening programs worldwide.  This review
attempted to answer the question of how best to measure overdiagnosis in order to first help patients,
physicians, and policy-makers make decisions about the benefits and harms of screening programs.
Second, being able to measure overdiagnosis will enable us to monitor it over time.  We believe that
ecologic studies performed by unbiased researchers in a variety of settings will provide the most accurate
view of the magnitude of overdiagnosis as well as the best way to monitor it over time.  Some of this
research is already ongoing, especially in European countries with breast cancer screening programs, but
it is not being performed in a uniform way. Standards should be developed for these studies that can then
be applied to data from different countries and can be used in a consistent way to monitor overdiagnosis
as we implement interventions to reduce it.
These standards should include an adequate time-frame that achieves sufficient follow-up of
women post-screening, such that all women in the post-screening age groups included in the study have
previously been offered screening.  Researchers should determine standard population-level confounders
that should be monitored and adjusted for.  The standards should include some considerations of
uncertainty, such as the use of multiple control groups or the performance of sensitivity analyses.  There
should also be standards for analysis that require overdiagnosis to be calculated as an absolute excess of
cases (or other variations on this numerator) divided by a denominator of cases diagnosed during the
screening period only (screen-detected cases, ideally).  Many authors make the mistake of including cases
diagnosed during the post-screening follow-up period or of representing overdiagnosis as the ratio of
cumulative incidences of the screened and unscreened populations over the screening and follow-up
periods, both of which dilute the true amount of overdiagnosis.  The uniform application of these
standards to data sets from different countries over different time frames and with a variety of screening
schedules and populations should move us closer to understanding the magnitude of overdiagnosis
present.
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Conclusions
Researchers have measured overdiagnosis using four main study types.  Modeling studies use
statistical models to measure overdiagnosis and are able to bypass areas of uncertainty but are limited by
their assumptions and indirectness.  Pathologic and imaging studies measure overdiagnosis based on a
tumor’s pathologic or imaging characteristic.   These studies lack directness and oversimplify cancer
progression and overdiagnosis.  Randomized controlled trials that do not offer screening to the control
group at the end of the trial period can follow subjects and measure overdiagnosis by comparing
incidence after long periods of time.  These studies best manage confounding but require a significant
time commitment.  Ecologic and cohort studies measure overdiagnosis by comparing cancer incidence in
a screened and unscreened population or cohort over a certain time frame.  Although these studies can be
limited by confounding and require adequate time frames and careful analysis, when performed well they
can provide a clear view of overdiagnosis.  This view can be clarified further as ecologic studies from
multiple settings and time frames are compared and demonstrate similar magnitudes of overdiagnosis.
We recommend that unbiased researchers use standards to perform such ecologic studies to monitor
overdiagnosis in cancer screening programs worldwide.
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Appendix A:  Standard Criteria for Evaluating Risk of Bias, by Study Design
Cohort and Ecologic Studies (adapted from Harris et al, 201138)
A. Risk of Bias (rate overall as high/moderate/low)
i. Probability of selection bias and confounding (rate as high/moderate/low)
i. Unbiased creation of comparable groups (at least after adjustment), especially
with regard to factors associated with cancer incidence
ii. Maintenance of comparable groups.  No large in or out migration during study
period; no large drop-outs or differential drop-outs.  No differential changes in
factors associated with cancer incidence.
iii. Adequate identification of potential confounders and control of potential
confounding by exclusion, stratification, statistical adjustment, other
ii. Probability of measurement bias (rate as high/moderate/low)
i. Measures of exposure to screening, potential confounders (especially factors
related to cancer incidence), and cancer incidence are equally applied between
comparison groups
ii. Measures of exposure to screening, potential confounders, and cancer incidence
are valid, including blinding where appropriate.
iii. Measures of exposure to screening, potential confounders, and cancer incidence
are reliable
Follow-up of Randomized Controlled Trial (adapted from the USPSTF Procedure Manual39)
A. Risk of Bias (rate overall as high/moderate/low)
i. Probability of selection bias (rate as high/moderate/low)
i. Unbiased creation of comparable groups, including adequate randomization,
allocation concealment, and equal distribution of potential confounders among
both groups
ii. Maintenance of comparable groups.  No large drop-outs or differential drop-outs.
Appropriate adherence and minimal contamination or cross-overs.
ii. Probability of measurement bias (rate as high/moderate/low)
i. Measures of exposure to screening, potential confounders, and cancer incidence
are equal between groups
ii. Measures of exposure to screening, potential confounders, and cancer incidence
are valid, including blinding where appropriate
iii. Measures of exposure to screening, potential confounders, and cancer incidence
are reliable
iii. Potential for confounding (rate as high/moderate/low)
i. Equal distribution of potential confounders among two groups, without changes
in group composition throughout follow-up.
Pathologic and Imaging Studies
A. Risk of Bias (rate overall as high/moderate/low)
i. Probability of selection bias and confounding (rate as high/moderate/low)
i. No large drop-outs or inadequate follow-up of selected members of study
population
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ii. If control group present: unbiased creation and maintenance of comparable
groups
iii. If control group present: adequate identification of potential confounders and
control of potential confounding by exclusion, stratification, statistical
adjustment, other
ii. Probability of measurement bias (rate as high/moderate/low)
i. Measures of pathologic or behavioral characteristics are valid, including
blinding where appropriate and avoiding differential follow-up
ii. Measures of pathologic or behavioral characteristics are reliable
Modeling Studies
A. Risk of Bias (rate overall as high/moderate/low)
i. Extent to which assumptions made in the model are transparent and clearly stated (rate as
good/fair/poor)
ii. Extent to which assumptions made in the model are backed up with evidence (rate as
good/fair/poor)
i. ideally systematically-reviewed evidence that was critical appraised with quality
ratings
iii. Probability for biases in the data used in the model (rate as good/fair/poor/cannot
determine)
i. Measurement of outcomes in data used in model are valid and reliable
ii. Adequate measurement of and control for potential confounders in data used in
model
1. This information should be presented and discussed by authors so that
readers can appraise the study.
iv. Extent to which sensitivity analyses are performed for any uncertain variables (rate as
good/fair/poor)
i. ideally probabilistic multivariate sensitivity analyses
v. Validation:  model has been validated using population data different from the population
data used to calibrate the model
Appendix B:  Criteria for Evaluating Strength of Evidence
A. Risk of Bias (rate as high/moderate/low) (specific criteria listed in Appendix A)
B. Analysis (rate as good/fair/poor) (Ecologic and Cohort, RCT follow-up studies only)
i. Extent to which the analysis appropriately quantifies overdiagnosis, without inclusion of
age groups or time frames that lack the potential to be overdiagnosed, and with
appropriate consideration for lead time
ii. Extent to which the time frame is appropriate sufficient to account for the effects of lead
time
C. Directness (rate as good/fair/poor)
i. Extent to which the evidence links the screening test directly to health outcomes with
minimal assumptions regarding:
i. The progression of a screen-detected cancer to a cancer that causes morbidity and
mortality
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ii. The association of pathologic or behavioral characteristics of a cancer with
cancer progression and cancer-related morbidity and mortality
D. External Validity (rate as good/fair/poor)
i. Extent to which study population is similar to US general population in factors that are
associated with cancer incidence
ii. Extent to which the screening situation (e.g., expertise of the screening radiographers,
quality of screening facilities, threshold for labeling a result as abnormal) in the study is
comparable to the screening situation in the US general population
iii. Extent to which medical care and risks for competing mortality in the study are similar to
medical care in the US general population
E. Precision (rate as good/fair/poor/cannot determine)
i. Confidence interval on magnitude of overdiagnosis should be provided.  Width of
confidence interval should be narrow.
F. Consistency (rate as good/fair/poor)
i. Degree to which the overdiagnosis measurement from the included studies has a similar
magnitude, within the same cancer type and study design
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Appendix C: Results
Appendix Table 1: Excluded Modeling Studies with Reasons for Exclusion
Study Reason for Exclusion
Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection
due to prostate-specific antigen screening: Estimates from the
European randomized study of screening for prostate cancer. J
Natl Cancer Inst. 2003;95(12):868-878
Same model and population as
Heijnsdijk 2009 (MISCAN model
fitted to ERSPC Rotterdam data)
Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen
screening for prostate cancer: A computer model evaluates
competing strategies. J Urol. 1999;162(3 I):741-748
same model and population as Etzioni
2002 and Telesca 2008
Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to
prostate-specific antigen screening: Lessons from U.S. prostate
cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-
990
Same model and population as Telesca
2008
Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R.
Calibrating disease progression models using population data:
A critical precursor to policy development in cancer
control. Biostatistics. 2010;11(4):707-719
Same model and population as Gulati
2013
Yen M, Tabar L, Vitak B, Smith RA, Chen H-, Duffy SW.
Quantifying the potential problem of overdiagnosis of ductal
carcinoma in situ in breast cancer screening. Eur J Cancer.
2003;39(12):1746-1754
Does not include invasive cancers,
only looks at overdiagnosis of DCIS
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Appendix Table 2: Evidence Table of Modeling Studies
Study,
Cancer
Type Model Name/Type
Modeled
Population,
Time Period
Screening Schedule/
Details Data Sources
Davidov
2004,
prostate Not provided
US men
Not provided
5-year intervals
starting at 50 and
ending at 60, 70 or 80
 Incidence: SEER 1993-1997
 Mortality: SSA life tables (1997 males)
Draisma
2009,
prostate
 MISCAN
(microsimulation)
 Fred Hutchinson
Cancer Research
Center
(microsimulation)
 UMich (statistical
mixed)
US men 54-80
Not provided
Not specified.
Screening patterns
based on typical US
screening
 Incidence: SEER 1985-2000
 Mortality: standard life tables
 PSA screening patterns: NHIS 2000 and SEER-linked
Medicare claims
 PSA growth curves: Prostate Cancer Prevention Trial
(FHCRC)
 Biopsy sensitivities: literature review (FHCRC)
 Biopsy compliance rates (40%): PLCO trial (FHCRC)
Gulati
2013,
prostate
Fred Hutchinson
Cancer Research
Center
(microsimulation)
US men aged 40
Not provided
32 different screening
strategies based on
variations of:
 starting at 40 or 50
 stopping at 69 or 74
 annual vs biennial
 4 thresholds for
biopsy referral
 Incidence: SEER 1975-2000, men 50-84
 Mortality: US life tables
 PSA screening patterns: NHIS 2000 and SEER-Medicare
linked claims
 PSA growth curves: control group from Prostate Cancer
Prevention Trial
 Prostate cancer treatment patterns: SEER 2005
 Baseline prostate cancer survival: SEER data on untreated
patients (1983-1986)
 Survival benefit for radical prostatectomy: SPCG-4 trial
 Survival benefit for radiotherapy: CaPSURE trial
 Survival benefit for early detection: ERSPC trial
 Biopsy compliance rates: PLCO trial
 Biopsy sensitivity: literature review
Heijnsdijk
2009,
prostate
MISCAN
(microsimulation)
European Standard
Population 2003,
2008-2033
55-70 every 1 or 2
years or 55-75 every
4 years, 3ng/ml
biopsy threshold
 Disease and treatment-specific parameters: Rotterdam
ERSPC
 Cure rates: estimated from 10-year relative survival by
clinical stage from Comprehensive Cancer Center
Amsterdam (1985-2005)
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Study,
Cancer
Type
A. Includes
DCIS?
B. Includes
Competing
Mortality?
C. External
Validation?
D. Reports
Preferred
Outcome?
Magnitude of
Overdiagnosis
(95% CI) Sensitivity Analyses?
Results of Sensitivity
Analyses Conclusions
Davidov
2004,
prostate
A.N/A
B.Yes
C.No
D. Unclear
8.48-53.6%,
depending on mean
sojourn time
Varied mean sojourn time (5,
7.5, 10, 12.5, 15 years) and
sensitivity (0.3, 0.7, 0.9)
Overdiagnosis did not
vary with sensitivity but
did vary greatly with
mean sojourn time
The probability of
overdiagnosis is remarkably
high.
Draisma
2009,
prostate
A.N/A
B.Yes
C.No
D.Yes
 MISCAN:  42%
 FRCHC:  28%
 UMich:  23% Not performed N/A
The precise definition and
population used to estimate
overdiagnosis can be important
drivers of study results.
Gulati
2013,
prostate
A.N/A
B.Yes
C.No
D.No
Lifetime probability
of overdiagnosis
ranges from 1.8-6%
Varied rates of disease onset,
metastasis, and clinical
detection in incidence model
and extent of screening effect in
mortality model.
Varied survival effect of
screening from no effect to
effect consistent with stage-
shift model.
Results not reported.
Authors report that
varying inputs produced
little variation and
overall conclusions
about tradeoffs across
strategies are robust.
Screening strategies that use
higher biopsy thresholds for
older men and screen men with
low PSA levels less frequently
achieve similar benefits in
mortality with fewer false
positives and cases
overdiagnosed.
Heijnsdijk
2009,
prostate
A.N/A
B.Yes
C.No
D.Yes
(estimate
from
figures)
 Screening every 4
years: 67%
 Screening
annually: 60%
 Screening
biennially: 60% Not performed N/A
Implementation of PSA
screening will double total costs
for prostate cancer, most of
which are due to diagnosis and
treatment, especially of
overdiagnosed cases.
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Study,
Cancer
Type
Model
Name/Type
Modeled
Population,
Time Period
Screening Schedule/
Details Data Sources
McGregor
1998,
prostate Not provided
Quebec men 50-85
Not provided
Annual PSA from 50-
70 with 4 ng/ml biopsy
threshold
 Rate of death from prostate cancer in 1980s assumed to
equal rate of lethal prostate cancer entering the population
 Prostate cancer mortality: Quebec Ministry of Health
(1988-1992)
 Proportion of lethal cancer detectable by PSA estimated
from literature review as 85%
Pashayan
2009,
prostate Not provided
UK men
Not provided
Single PSA test with
3ng/ml biopsy threshold
 Incidence: Eastern Cancer Registry and Information Centre
 Prevalent cases:  ProtecT study
 Interval cancers:  UK Office of National Statistics 2002-
2005
 Mortality: UK Office of National Statistics male life tables
 PSA sensitivity by age: determined by linear regression
from values obtained from literature review
Telesca
2008,
prostate
Stochastic
simulation model
US men 50+
Not provided
Not specified.
Screening patterns
based on typical
screening in US
 Incidence: SEER 1973-1987
 Mortality: CDC’s Vital Statistics of the US 1992
 PSA screening patterns: NHIS 2000 and SEER-Medicare
linked claims
 Probability of a positive test among men screened, biopsy
frequency given positive test, and PPV obtained from
literature search
Tsodikov
2006,
prostate Not provided
US men
Not provided
Not specified.
Screening patterns
based on typical
screening in US
 Incidence: SEER
 Mortality: Human Mortality Database
 PSA screening patterns: NHIS 2000 and SEER-Medicare
linked claims
 PSA sensitivity = 100%
Wu 2012,
prostate
Multistep
epidemiological
model/ five-state
Markov model
Finnish men ages 55,
59, 63, 67
Not provided
Up to 3 PSA tests every
4 years until 71 with 4
ng/ml threshold for
DRE, ultrasound and
biopsy.  If PSA 3-3.9
ng/ml, referred for DRE
or free/total PSA ratio
 Incidence: Finnish prostate cancer screening trial (largest
arm of ERSPC), 1996-2005
 Interval cancers:  Finnish Cancer Registry
 Mortality:  Statistics Finland
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Study,
Cancer
Type
A. Includes
DCIS?
B. Includes
Competing
Mortality?
C. External
Validation?
D. Reports
Preferred
Outcome?
Magnitude of
Overdiagnosis (95% CI) Sensitivity Analyses?
Results of
Sensitivity
Analyses Conclusions
McGregor
1998,
prostate
A.N/A
B.Yes
C.No
D.Yes 84%
Varied detection rates of
lethal cancer with PSA from
75% to 95% 78 to 87%
Of every 100 men with screen-
detected prostate cancer, only 16 on
average could have their lives
extended by surgery since the cancer
would not cause death before age 85
in the remaining 84.
Pashayan
2009,
prostate
A.N/A
B.Yes
C.No
D.Yes
 Ages 50-54: 10% (7-11)
 Ages 55-59: 15% (12-15%)
 Ages 60-64: 23% (20-24%)
 Ages 65-69: 31% (26-32%) Not performed N/A
The benefit of screening in reducing
advanced stage disease is limited by
overdiagnosis, which is greater at
older ages.
Telesca
2008,
prostate
A.N/A
B.Yes
C.No
D.Yes
 White men: 22.7%
 Black men:  34.4%
Authors considered a constant
secular incidence trend and a
decreasing trend to account
for decline in use of TURP
for BPH.  As sensitivity
analysis, also considered an
increasing trend.
Results not
reported
Likelihood-based approach allows
authors to make formal inferences
about lead time and overdiagnosis
associated with PSA screening in US
Tsodikov
2006,
prostate
A.N/A
B.Yes
C.No
D.Yes About 30% Not performed N/A
Wu 2012,
prostate
A.N/A
B.Yes
C.No
D.No
Absolute risk for
overdetection during study
period 3.4% (2.1-5.7%) Not performed N/A
Authors estimated that for every 100
men screened, 3.4 cases would be
overdetected during 3 screening
rounds in the Finnish trial.
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Study,
Cancer
Type
Model
Name/Type
Modeled
Population,
Time Period
Screening Schedule/
Details Data Sources
De Gelder
2011 (Epi
Reviews),
breast
MISCAN
(micro-
simulation)
Dutch female
population 0-100 in
1989,
Not provided
Biennial screening began in
1990, gradually spread to
all of Netherlands by 1997
for women 49-69.
Extended to women 49-74
between 1998-2001
 Incidence: Dutch Comprehensive Cancer Centers and
National Evaluation Team for Breast Cancer Screening
in the Netherlands, 1990-2006
De Gelder
2011
(Preventive
Medicine),
breast
MISCAN
(micro-
simulation)
Dutch female
population 0-100 in
1989,
1990-2020
30-year period of biennial
screening with either screen
film mammography or
digital mammography
 Incidence: Dutch  Cancer Registry and National
Evaluation Team for Breast Cancer Screening, 1990-
2006
 Screening patterns: 82% participation rate based on
NETB data
 100% sensitivity of digital mammography for DCIS
Duffy
2005,
breast Not provided
 Swedish 2-County
Trial: women 40-74
 Gothenburg Trial:
women 39-59,
Not provided
 Swedish 2-County:
single-view
mammography biennially
(40-49) and every 33
months (50-74)
 Gothenburg: 2-view
mammography at first
screen, # of views then
dependent on breast
density, every 18 months
 All Data: Swedish 2-Country RCT (1977-84) and
Gothenburg RCT (1982-1987) (separate analyses)
Gunsoy
2012,
breast
Markov models
for screening
parameter and
overdiagnosis
estimation
UK women 40-49,
Not provided
Annual screening
mammography from ages
40-49
 Parameter estimation model:  all data from Age RCT
(1991-2010)
 Overdiagnosis model:
 Incidence:  England and Wales Office of National
Statistics 2008 (women 40-54), control arm of Age RCT
(women 40-49)
 Mortality:  England and Wales Office of National
Statistics 2008
 Mean sojourn time: estimated from literature review (in
addition to parameter estimation model)
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Study,
Cancer
Type
A. Includes
DCIS?
B. Includes
Competing
Mortality?
C. External
Validation?
D. Reports
Preferred
Outcome?
Magnitude of
Overdiagnosis (95% CI) Sensitivity Analyses?
Results of
Sensitivity
Analyses Conclusions
De Gelder
2011
(Epi
Reviews),
breast
A.Yes
B.Yes
C.No
D.Yes
 Implementation:  22.1-
67.4%
 Extension:  15.4-30.4%
 Steady state:  8.9-15.2% Not performed N/A
Overdiagnosis depends on
year calculated (earlier in
screening programs find
higher rates) and denominator
De Gelder
2011
(Prev
Med),
breast
A.Yes
B.Yes
C.No
D.Yes
 Screen film
mammography:  7.2%
 Digital mammography:
8.2%
Considered two alternative
models:
 Progressive model, where all
tumors pass through screen-
detectable DCIS phase and
none regress
 Nonprogressive model, where
no tumors pass through
screen-detectable DCIS stage
and majority of preclinical
DCIS regresses
 Progressive model:
film- 4.6%, digital-
5.0%
 Nonprogressive
model: film-
19.2%, digital-
25.2%
Modeling predicted that
digital mammography
screening would further
reduce breast cancer mortality
by 4.4% at a 21% increased
overdiagnosis rate.  Outcomes
are sensitive to underlying
assumptions on natural
history of DCIS.
Duffy
2005,
breast
A.Yes
B.No
C.No
D.Yes
 Swedish: 1st screen 3.1%
(0.1-10.9), 2nd screen
0.3% (0.1-1), 3rd screen
0.3% (0.1-1).
 Gothenburg: 1st screen
4.2% (0.0-28.8), 2nd
screen 0.3% (0.0-2.0),
3rd screen 0.3% (0.0-2.0) Not performed  N/A
Overdiagnosis in
mammography screening is a
minor phenomenon.
Gunsoy
2012,
breast
A.Yes
B.Yes
C.No
D.Yes 0.70%
Varied sensitivity and mean
sojourn time in combinations:
high MST, low MST, high sens,
low sens, high MST with low
sens, high MST with high sens
0.5% to 2.9%
Increasing MST had
a greater impact than
did increasing
sensitivity.
In UK women 40-49, a small
proportion of breast cancers
were overdiagnosed due to
screening.
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Study,
Cancer
Type
Model
Name/Type
Modeled
Population,
Time Period
Screening
Schedule/ Details Data Sources
Martinez-
Alonso
2010,
breast
Poisson
regression age-
cohort model
and probabilistic
model
Catalan women ages
25-84,
1980-2004
Biennial
mammography from
ages 50-69
 Incidence: Girona Cancer Registry (1980-9, 1991-2004) and
International Agency for Research on Cancer (IARC) registry for
Tarragona (1983-97)
 Incidence model includes completed fertility rate where relative
risk of breast cancer 0.85 per child born based on literature
review
 Mean sojourn time ranges from 2-4, depending on age
 Mammography sensitivity ranges from 0.35 to 0.8, depending on
age
Olsen
2006,
breast Not provided
Copenhagen women
50-69,
Not provided
Biennial
mammography from
ages 50-69
 Incidence:  Danish Cancer Registry and Danish Breast Cancer
Cooperative Group
 Interval cancers: Danish Cancer Registry and Central Population
Registry
 Screening patterns: Copenhagen mammography database
 Mammography sensitivity: set at 100% in primary analysis
Seigneurin
2012,
breast
Approximate
Bayesian
computation
analysis with a
stochastic
simulation
model
Women 50-69 in
Isere, France,
1991-2006 Not specified
 Incidence: French population-based study by Seigneurin 2009
 Screening patterns:  surveys for 1991-2 and 2005-6, assumed that
screening mammography dissemination followed linear trend
from 1991-2006, opportunistic screening assumed to be a
maximum of 40%
 Mean sojourn time: 2-4 years based on literature review
 Mammography sensitivity: mean assumed to be 90%
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Study,
Cancer
Type
A. Includes
DCIS?
B. Includes
Competing
Mortality?
C. External
Validation?
D. Reports
Preferred
Outcome?
Magnitude of
Overdiagnosis (95% CI) Sensitivity Analyses? Results of Sensitivity Analyses Conclusions
Martinez-
Alonso
2010,
breast
A.No
B.Yes
C.No
D.No
 1935 birth cohort: 0.4%
(-8.8 to 12.2)
 1940: 23.3% (9.1-43.4%)
 1945: 30.6% (12.7-
57.6%)
 1950: 46.6% (22.7-
85.2%)
Calculated as excess
divided by expected
incidence
Varied mean sojourn
time to be 1 and 5
Set mammography
sensitivity to 0.9
Varying MST from 1 to 5 changed
overdiagnosis from 51.1 to 18.3%.
Increasing sensitivity did not greatly
affect estimates.
Results support the
existence of
overdiagnosis in
Catalonia
attributable to
mammography.
Olsen 2006,
breast
A.Yes
B.No
C.No
D.Yes
 1st screen 7.8% (0.3-
27.5)
 2nd screen: 0.5% (0.01-
2.2%)
Varied sensitivity to be
80% and 90%
 Sensitivity 90%: first screen 8.3%
(0.3-29.1), second screen 0.6% (0.02-
2.4)
 Sensitivity 80%: first screen 8.6%
(0.3-28.4), second screen 0.6% (0.02-
2.3)
A modest
overdiagnosis was
estimated from the
Copenhagen
screening program,
almost exclusively
from first screen.
Seigneurin
2012,
breast
A.Yes
B.No
C.No
D.Yes
 DCIS: 31.9% (2.9-62.3)
 Invasive cancer: 3.3%
(0.7-6.5)
 Varied sojourn time
distribution and
parameters
 Excluded the 1991-5
study period which had
more prevalent screens
at the beginning of the
screening program
 Varied distribution of
non-progressive
carcinoma in-situ
 Varying sojourn time: overdiagnosis
of DCIS varied from 17.3% (7.8-
28.5) to 51.7% (15.4-81.8), invasive
cancer from 0.0% (0.0-0.1) to 8.9%
(0.5-24.0)
 Excluding 1991-5 study period did
not greatly affect results.
 Uniform prior distribution of non-
progressive CIS greatly altered point
estimate of overdiagnosis proportion
(7.5% instead of 28.0%) but did not
improve precision (95% CI 0-45.1%)
Overdiagnosis from
the detection of
non-progressive
disease by
screening
mammography was
limited in 1991-
2006 in Isere.
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Study,
Cancer
Type
Model
Name/Type
Modeled
Population,
Time Period
Screening
Schedule/ Details Data Sources
Hazelton
2012,
lung
Longitudinal
multistage
model
Current or former
heavy smokers with
< 5 years asbestos
exposure,
Not provided Low dose CT
 Incidence: Carotene and Retinol Efficacy Trial (calibration)
 Mortality: CARET (calibration)
 CT screening data: Pittsburgh Lung Screening Study (calibration)
 Calibrated model applied to NYU Biomarker Center trial and
Moffitt Cancer Center trial
 Literature search for number of stem cells in lungs and density of
malignant stem cells per unit volume
 Data on pulmonary tumor size at incidence and death from Geddes
1979 review
Pinsky
2004,
lung
Early- and
late-stage
convolution
model
Men 50-75 with
smoking patterns
similar to those of
Mayo Lung Trial
participants,
Not provided
CXR and sputum
cytology annually
from ages 50-75
 All data: Mayo Lung Cancer Screening Trial (prevalence screen and
screening arm)
Luo 2012,
colon
Not
provided
Hypothetical
cohorts with ages
40, 50 or 60 at first
screening,
Not provided
5 annual or 3
biennial FOBT tests,
starting at ages 40,
50 or 60
 Incidence: Minnesota Colon Cancer Control study (1976-1982)
 Mortality: actuarial life tables from US SSA
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Study,
Cancer Type
A. Includes
DCIS?
B. Includes
Competing
Mortality?
C. External
Validation?
D. Reports
Preferred
Outcome? Magnitude of Overdiagnosis (95% CI) Sensitivity Analyses?
Results of Sensitivity
Analyses Conclusions
Hazelton
2012,
lung
A.N/A
B.Yes
C.No
D.Yes
 Detection of indolent nodules is 7.0%
(4.9-11.7%) for men and 33.0% (26.9-
36.9%) for women.
 Additional 2.2% (2.0-2.4%) for women
and 7.1% (6.7-8.0%) for men are
overdiagnosed Not performed N/A
Significant gender
differences in
progression of lung
cancer, where female
patients have much
higher rates of
indolent cancers.
Pinsky 2004,
lung
A.N/A
B.Yes
C.No
D.Yes 13-17% Not performed N/A
Luo 2012,
colon
A.N/A
B.Yes
C.No
D.Yes
• Females, ages 40, 50, 60:  6.50%,
6.65%, 7.33% (95% CI 2.56- 20.49%)
• Males, ages 40, 50, 60: 5.61%, 6.15%,
7.48% (95% CI 1.92-44.69%) Not performed N/A
Probability of
overdiagnosis among
screen-detected cases
is not as high as
previously thought.
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Appendix Table 3: Criteria for Evaluating Risk of Bias and Strength of Evidence for Modeling Studies
Study
Cancer
Type
Assumptions
Transparent
and Clearly
Stated
Assumptions
Backed with
Evidence
Probability
for Biases in
Model Data
Sensitivity
Analyses
External
Validation
Overall
Risk of
Bias
Overall
External
Validity Precision
G/F/P G/F/P H/M/L/CD G/F/P Y/N H/M/L G/F/P G/F/P/CD
Davidov 2004 prostate F F CD F N M G CD
Draisma 2009 prostate F F CD P N H G CD
Gulati 2013 prostate G F CD F N M G CD
Heijnsdijk 2009 prostate F F CD P N H F CD
McGregor 1998 prostate F F CD P N H F CD
Pashayan 2009 prostate F F CD P N H F G
Tsodikov 2006 prostate F F CD P N H G CD
Wu 2012 prostate F F CD P N H F F
De Gelder 2011 (ER) breast F F CD P N H F P
De Gelder 2011 (PM) breast F F CD P N H F CD
Duffy 2005 breast F G CD P N H F F
Gunsoy 2012 breast F F CD F N M F CD
Martinez-Alonso 2010 breast F F CD F N M F P
Olsen 2006 breast F F CD P N H F F
Seigneurin 2012 breast F F CD F N M F P
Hazelton 2012 lung F F CD P N H G G
Pinsky 2004 lung F F CD P N H F CD
Luo 2012 colon P F CD P N H F P
Criteria used in strength of evidence evaluation are bolded.  Abbreviations: G, good; F, fair; P, poor; CD, cannot determine; H, high; M, moderate;
L, low; ER, Epidemiologic Reviews; PM, Preventive Medicine.
79
Appendix Table 4:  Evidence Table of Pathologic and Imaging Studies
Study,
Cancer Type,
Study Period Study Population
Comparison
Group?
Screening
Situation Pathologic/Behavioral Outcome
Dominioni
2012,
Lung,
1997-2011
21 Italians with screen-detected
cancer during study period, with
>10 pack-year smoking history,
45-75, fit for thoracotomy,
asymptomatic No
Baseline CXR with
annual repeat
screen for 4 years
Volume doubling time (VDT).  Overdiagnosis
defined as VDT>300 days
Lindell 2007,
Lung,
1999-2004
20+ pack-year smoking history
Cancers studied were 61 tumors
in 59 US patients, 24 men/37
women, ages 53-79 (mean 65) No
Chest CT
performed at
baseline and every
12 months
thereafter for 5
years
Volume doubling time.  Overdiagnosis defined as
VDT >400 days
Sobue 1992,
Lung,
1976-1989
Patients screened in Japanese
Lung Cancer Screening
Research Group from 1976-81
who did not undergo surgical
treatment (42 cases)
Symptom-
detected
controls
matched by
age, sex, and
year of
diagnosis (27
cases) Chest X-ray
Overdiagnosis defined as dying from a cause other
than lung cancer in patients diagnosed with clinical
stage 1 disease (all study patients)
Sone 2007,
Lung,
1996-1998
45 patients ages 40-74 (smokers
and non-smokers) with lung
cancer detected in CT screening
program for whom repeat CT
images were available, in rural
Japan from 1996-1998 No
Low-dose CT scan,
with immediate
work-up for
suspicious lesions
and 3-month
delayed workup for
nodules <3mm
Calculated patients' expected time of death by
calculating age when tumor would reach 30 mm,
based on tumor size at detection and VDT, then
adding 2 years. If expected age of death was higher
than average life span in Japan (78.64 for males,
85.59 for females), cancer was considered
overdiagnosis.
Veronesi 2012
Lung
2004-2010
120 Italian patients with incident
lung cancer detected in CT
screening program (COSMOS)
study, all with > 20 pack-years,
70% men, ages 50+ No
annual low-dose
CT scan for 5
consecutive years,
without notification
for nodules <5mm
Cancer with VDT <400 days defined as fast-growing,
VDT between 400-599 days defined as slow-
growing, and VDT>600 days defined as indolent.
Considered VDT>400 days to be overdiagnosis
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Study,
Cancer Type Outcome Assessment Results
Preferred
Outcome?
Magnitude of
Overdiagnosis Conclusions
Dominioni
2012,
Lung
VDT based on tumor size
measurements from sequential CXRs,
read by one of 3 senior radiologists.  If
tumor not evident retrospectively,
assigned dimension of 6mm.
Median VDT 80 days (range
44-318).
Only one cancer had VDT>300 No "Minimal"
Low median volume
doubling time
suggests that
overdiagnosis was
minimal.
Lindell 2007,
Lung
CTs reviewed retrospectively by one
radiologist who measured 2 diameters
with electronic calipers to calculate
VDT with modified Schwartz equation
for all tumors with at least 2 CT scans
available.
4 tumors became smaller at
some point during the study.
13/48 tumors (27%) had VDT
longer than 400 days.
11/13 (85%) with VDT>400
days in women. No 27%
Overdiagnosis,
especially in women,
may be a substantial
concern in lung
cancer screening.
Sobue 1992,
Lung
Death certificates and medical records
reviewed
20% of screen-detected and
19% of symptom-detected
patients died from cause other
than lung cancer No "Minimal"
Overdiagnosis bias
would be minimal in
screen-detected lung
cancer cases detected
by CXR.
Sone 2007,
Lung
Tumor growth assessed on high
resolution CT, based on largest tumor
diameter.  VDT calculated with
Schwartz formula
13.3% (6 of 45 cases) overall
were considered overdiagnosed
(17.9% of male patients, 5.9%
of female patients, and 40% of
non-solid lesions) No 13.30%
Estimated rate of
possible
overdiagnosis was
13% in total.
Veronesi 2012
Lung
VDT calculated using Lesion
Management Solutions-lung software.
If software unable to estimate volume,
electronic calipers used to measure
largest axial diameter and VDT
calculated with formula from
Yankelevitz 2000.  To estimate VDT
for a new cancer, nodule assumed to be
2mm the previous year.
58.3% (49.0-67.3%) of incident
cases were fast growing and
25.8% (18.3-34.6%) were
slow-growing or indolent.
15.0% (9.1-22.7%) slow-
growing and 10.8% (5.9-
17.8%) indolent No
25.8% (18.3-
34.6%)
VDT analysis
suggests at least 75%
of cases were
aggressive,
downsizing problem
of overdiagnosis.
Among the 25% of
slow-growing or
indolent cases, many
are likely to be
overdiagnosed.
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Study,
Cancer Type,
Study Period Study Population
Comparison
Group? Screening Situation Pathologic/Behavioral Outcome
Yankelevitz
2003,
Lung,
Not provided
Patients diagnosed with stage 1
lung cancer from the screening
arms of the NY Lung Cancer
Detection Project at Memorial-
Sloan Kettering (MSK, 43 cases)
and Mayo Lung Project (MLP,
44 cases). No
MSK: sputum cytology every 4
months with annual CXR
MLP: sputum cytology and CXR
every 4 months
Volume doubling time. VDT> 400
days considered overdiagnosis
Graif 2007,
Prostate,
1989-2005
2126 US men with clinical stage
T1c  prostate cancer treated with
RRP. No
screening situation differed by "era"
of study.
Era 1:  PSA threshold 4ng/ml, with
quadrant biopsy for abnormal
results.
Era 2:  PSA threshold 2.5 ng/ml,
sextant biopsy for abnormal.
Era 3:  men who were referred for
RRP, no standard biopsy strategy.
Overdiagnosis defined as tumor
volume <0.5 cm3, Gleason <7, organ-
confined disease in RRP specimen
with clear surgical margins
Pelzer 2008,
Prostate,
1999-2006
997 patients with prostate cancer
undergoing RRP from Tyrol,
Austria and nearby areas.
Patients treated with hormonal,
chemo or radiotherapy were
excluded.   806 of these were
Tyrolean screening volunteers
("screened group")
191 patients
were
referred for
RRP from
outside
Tyrol
("referral
group")
PSA testing with elevated PSA
leading to referral for biopsy with 10
cores until 2000 and 15 from 2000-
2006
Overdiagnosis defined as Gleason
<7, pathologic stage of pT2a and
negative surgical margins
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Study,
Cancer Type Outcome Assessment Results
Preferred
Outcome?
Magnitude of
Overdiagnosis Conclusions
Yankelevitz
2003,
Lung
 MSK: Tumor length and width
obtained for at least 2 time points or
with documented invisibility at prior
time.  Visibility threshold calculated
to be 0.6cm.
 MLP: Used frequency distribution of
tumor dimension and disease stage at
time of diagnosis and number of
months tumor visible in retrospect,
assuming stage 1 malignancies were
the smallest (no dimension and stage
information available for individual
tumors)
 MSK: 3/43 (7%) of cases had
VDT>400 days
 MLP: 1/44 (2%) of cases had
VDT>400 days
 5% of overall cases had
VDT>400 days No 5%
The hypothesis that
early-stage lung
tumors on chest
radiography during
lung cancer screening
may frequently be
overdiagnosed,
indolent cases needs
to be rejected.
Graif 2007,
Prostate
No info on RRP procedures.  Visual
estimation of percent cancer in prostate
gland used in majority of cases, but
some cases used grid morphometric
method.  Tumor volume calculated
from % cancer multiplied by volume of
RRP specimen
4.5% of men undergoing RRP
during study period met criteria
for overdiagnosis compared
with 27% meeting criteria for
underdiagnosis.  5-year
progression-free survival of
men meeting overdiagnosis
criteria was 100%. No 4.50%
Underdiagnosis of
prostate cancer
continues to occur
more frequently than
overdiagnosis
Pelzer 2008,
Prostate
No info on RRP procedures.  Each
biopsy core reviewed by one
pathologist
Overdiagnosis was 16.8% in
the screening group and 7.9%
in the referral group No
 Screening
group:
16.8%
 Referral
group: 7.9%
Other reported
estimates of
overdiagnosis due to
screening are
exaggerated, and
underdiagnosis
should be the primary
concern.
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Appendix Table 5: Criteria for Evaluating Risk of Bias and Strength of Evidence for Pathologic and Imaging Studies
Study
Cancer
Type
Probability
for Selection
Bias and
Confounding
Probability
for
Measurement
Bias
Overall Risk
of Bias
Explanation of Link
Between Pathologic/
Imaging
Characteristic and
Cancer Progression Directness
External
Validity Precision
H/M/L H/M/L H/M/L G/F/P G/F/P G/F/P G/F/P/CD
Dominioni 2012 lung L M M P P F P
Lindell 2007 lung M M M P P F CD
Sobue 1992 lung H H H NA G P P
Sone 2007 lung H M H P P F CD
Veronesi 2012 lung L M M F P F F
Yankelevitz 2003 lung H H H P P F CD
Graif 2007 prostate H H H P P F CD
Pelzer 2008 prostate H M H P P F CD
Criteria used in strength of evidence evaluation are bolded.  Abbreviations: H, high; M, moderate; L, low; G, good; F, fair; P, poor; CD, cannot
determine
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Appendix Table 6: Evidence Table of Ecologic and Cohort Studies
Study;
Cancer
Type;
Study Design
Study
Population;
Time Period Description of Methods
Reference
Population
Screening
Schedule
Bleyer 2012;
Breast;
Ecologic
US women 40+
1976-2008
Using stage-specific incidence from SEER,  calculated excess
cases of early-stage cancer and reduction in number of late-
stage cancers by projecting baseline incidence pre-screening
and comparing to incidence each subsequent year.  Excess of
early-stage diagnoses not balanced by reduction in late-stage
diagnoses considered overdiagnosed.
baseline incidence of
breast cancer
determined from
SEER 1976-1978
trend data on
proportion of
women undergoing
mammography
estimated from
NHIS
Duffy 2010;
Breast;
Cohort and
Ecologic
Swedish 2-
County trial:
women 50-69;
1977-88
(screening),
1989-98 (post-
screening)
UK women 47-
73; 1974-89
(pre-screening),
1989-2003
(screening)
Swedish: estimated expected incidence based on incidence
trend in control group during first 6 years of trial.  Used
several equations to calculate rates of overdiagnosis.
UK: Determined expected incidence in 1989-2003 based on
trends from pre-screening period.  Took into account non-
linear trends by dividing expected numbers by relative excess
for <45 age group (unscreened). Overdiagnosis calculated as
excess of observed cases in ages 45-64 minus deficit in 65+
Swedish: control arm
of trial before
screening offered
UK: women from
1974-88, before
introduction of
screening
Swedish: women
40-49 offered
mammography
every 24 months,
50-74 every 33
months.
UK:
mammography
every 3 years
Falk 2013
Breast;
Cohort
Norwegian
women 50-69;
1995-2009
Incidence rate ratios calculated for women attending screening
compared to non-attenders, stratified by county, calendar year
and age.  Reference rates determined from reference
population, multiplied by IRR of screening participants to find
excess of cancer diagnoses during screening program and
deficit afterwards.  Overdiagnosis calculated as excess not
compensated by deficit in post-screening.
Reference rates by
age based on
observed rates of
invasive breast cancer
1980-4, chosen to
minimize influence of
HRT, standardized to
life table population
from Statistics
Norway based on
2010 morality rates.
biennial screening
with two-view
mammography
from ages 50-69
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Study;
Cancer
type
Screening in
Reference
Population
Management of Potential
Confounders
Management
of Lead Time
Calculation of
Overdiagnosis
A.Includes
DCIS?
B.Reports
preferred
outcome?
Magnitude of
Overdiagnosis
(95% CI)
Bleyer
2012;
Breast
Few cases of
DCIS detected
during 1976-8
Adjusted for HRT use by truncating
estimate of observed incidence from
1990-2005 if greater than incidence
from 2006-2008
Adjusted for baseline increasing
incidence based on the increase in
incidence of women <40 (0.25% per
year)
Long follow-
up/ steady-
state screening
(excess cases)/
(observed cases)
during screening
period
A. Yes
B. No
In 2008, 31% of all
breast cancers were
overdiagnosed.
Duffy
2010;
Breast Not discussed
UK: Adjusted for baseline increase in
incidence, including non-linear
increases
Swedish:
excluded
prevalence
screen in
calculations
UK: unclear.
Screening
program being
expanded to
ages 47-73 at
time of study
Based on
complex
calculation
A. Unclear
B. No
Swedish: 12% of all
cancers are
overdiagnosed
UK: 2.3 cases
overdiagnosed per
1000 screened for 20
years
Falk
2013;
Breast
Formal
screening
program began
in 1995
Calculation of IRRs stratified by
county, calendar year, and age.
Authors suggest that other confounders
like use of HRT almost entirely
accounted for by these variables.
10-year
follow-up
post-screening
program
(excess cases)/
(expected cases)
during screening
A. Yes
B. No 19.4% (11.8-27.0)
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Study;
Cancer type
Considerations of Uncertainty/
Sensitivity Analyses Results of Sensitivity Analyses Conclusions
Bleyer 2012;
Breast
Assumed baseline incidence increasing by
0.5% per year (twice that seen in women
<40) ("extreme" assumption) and with
revision of baseline incidence of late-stage
cancer using highest incidence observed in
data ("very extreme" assumption)
"Extreme" assumption: 26% of all
cases overdiagnosed
"Very extreme" assumption: 22% of all
cases overdiagnosed
Mammography has substantially increased
diagnosed of early-stage cancer while
minimally reducing late-stage diagnoses,
suggesting substantial overdiagnosis
accounting for a third of all diagnosed
cases.
Duffy 2010;
Breast Not performed
Worthwhile benefit of mammography in
terms of lives saved that significantly
exceeds any harm in the form of
overdiagnosis that may occur.
Falk 2010;
Breast
Used two other reference populations: a
modeled population of 40-year-old women
in 1993-95, and a historical cohort of
women born in 1903-1907
Also explored if there were differences in
breast cancer incidence among attending
and non-attending women by comparing
IRRs of women not yet invited to screening
to those not attending.
Modeled reference: 19.6% (12.1-27.1)
historical reference: 16.5% (9.1-23.9)
No differences between non-attenders
and women not yet invited below age
55, but above 55 non-attenders more
likely to have higher incidence of
DCIS and invasive cancer
Results highlight the need for individual
data with longitudinal screening history
and long-term follow-up as a basis for
estimating overdiagnosis.
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Study;
Cancer
Type;
Study Design
Study
Population;
Time Period Description of Methods Reference Population
Screening
Schedule
Hellquist
2012;
Breast;
Ecologic
Swedish women
40-49;
1986-2005
Calculated risk ratio for breast cancer among women in
counties offered screening compared to those not offered
screening, excluding cancers detected during the prevalence
screens and then adjusting for "trend bias" with a calculation
that includes increasing baseline incidence of breast cancer
and lead time
Swedish women 40-49 in
counties not invited to
screening.  In some counties
only certain years within
1986-2005 were selected to
achieve similar follow-up in
study and control groups
Not
provided
Jorgenson
2009 (BMJ);
Breast;
Ecologic
(systematic
review)
UK:  50-64
(1993-1999)
Manitoba, CA:
50-69 (1995-
2005)
New South
Wales: 50-69
(1996-2002)
Sweden: 50-69
(1998-2006)
Norway: 50-69
(2000-2006)
Systematic review to identify incidence trends where
incidence data on screening-age and older women was
available 7 years before and after screening fully
implemented.  If compensatory drop in post-screening ages
absent, calculated rate ratio between observed incidence for
last observation year (determined by linear regression over
time period when screening fully implemented) to expected
incidence calculated from pre-screening incidence trend.   If
compensatory drop present, calculated the size of the drop as a
rate ratio, and then determined the absolute deficit of breast
cancer cases per 100,000 women.  Calculated the percentage
of excess cases uncompensated by drop in post-screening
ages.  Included DCIS when not reported by assuming that it
would contribute 10% of the diagnoses
Used linear regression to
calculate expected incidence
in study population in
absence of screening from
pre-screening trends.  Pre-
screening period defined as
1971-84 in UK, 1970-78 in
Manitoba, 1972-87 in New
South Wales, 1971-85 in
Sweden, 1980-94 in Norway
Formal
mammograp
hy screening
programs by
country
Jorgenson
2009 (BMC)
Breast;
Ecologic
Danish women
50-69 in
Copenhagen and
Funen;
1991-2003
Compared incidence rates in screened and unscreened areas of
Denmark, using Poisson regression to adjust for age and
geographical differences in incidence in the pre-screening
period (1971-1991).  Quantified excess of cancers detected in
screened counties not balanced by decrease in cancers in
women post-screening age.
Other counties in Denmark
without screening programs
Biennial
mammo-
graphy, 63-
88%
attendance
Junod 2011;
Breast;
Ecologic
French women
50-64 and 65-
79;
1995-2005
Incidence compared for middle-aged and elderly women  from
1995-2005 to age-matched reference cohorts from 1980-90.
Incidence change attributable to HRT use, alcohol use, and
obesity was removed, and the remaining incidence difference
was considered overdiagnosis
Age-matched historical birth
cohorts from 1980-1990
Mammo-
graphy from
50-69,
extended to
74
88
Study;
Cancer type
Screening in
Reference
Population
Management of Potential
Confounders
Management of
Lead Time
Calculation
of over-
diagnosis
A.Includes
DCIS?
B.Reports
preferred
outcome?
Magnitude of
Overdiagnosis
(95% CI)
Hellquist
2012;
Breast
Certain counties
excluded if
screening formally
introduced.
Adjusted for differences in
baseline incidence between study
and control groups
statistical
adjustment for
lead time= 1.2
years
(excess
cases)/
(expected
cases) during
screening
A. Yes
B. No
1% (-6.0-8.0%)
Crude estimate
(including prevalence
screening w/o lead
time adjustment): 16%
(9-23%)
Jorgenson
2009 (BMJ);
Breast
Looked for abrupt
increase in DCIS
in pre-screening
years to indicate
opportunistic
screening and
chose a different
reference if
present
Accounted for baseline increasing
incidence with linear regression.
looked at incidence in women too
young to be screened to see if any
incidence growth not attributable
to screening present
Up to 7 year
follow-up post-
screening
(excess
cases)/
(expected
cases) during
screening
A. Yes
B. No
UK: 57% (53-61%)
Manitoba: 44% (25-
65%)
NSW: 53% (44-63%)
Sweden: 46% (40-
52%)
Norway: 52% (36-
70%)
Meta-analysis: 52%
(46-58%)
Jorgenson
2009
(BMC);
Breast
Expect that <10%
of women
participated in
opportunistic
screening
Used poisson regression to adjust
for differences in age and
geographical variation in pre-
screening incidence
Up to 10 to 12
years follow-up
post-screening
(excess
cases)/
(expected
cases) during
screening
A. Yes
B. No 33%
Junod 2011;
Breast
Opportunistic
screening is
substantial
Subtracted expected changes in
incidence due to HRT, alcohol,
and obesity.  Did not account for
baseline increase in incidence
between the historical and
contemporary cohorts Unclear
(excess
cases)/
(expected
cases) during
screening
A. No
B. No
Ages 50-64: 76% (67-
85%)
Ages 65-79: 23% (15-
31%)
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Study;
Cancer type
Considerations of Uncertainty/
Sensitivity Analyses Results of Sensitivity Analyses Conclusions
Hellquist
2012;
Breast Varied lead time from 1.0-1.5 years
Lead time 1 year: 2%
Lead time 1.5 years: -1%
Found no significant overdiagnosis for
women 40-49 in Swedish service
screening mammography program.
Jorgenson
2009 (BMJ);
Breast Not performed
The increase in incidence of breast cancer
was closely related to introduction of
screening and little was compensated for
by a drop in incidence in previously-
screened women.  One in three breast
cancers in a population offered screening
is overdiagnosed.
Jorgenson
2009
(BMC);
Breast Not performed
One in four breast cancers diagnosed in
the screened age group in Danish women
is overdiagnosed.  Estimate is lower than
for comparable countries because of lower
uptake, recall rates and diagnosis of CIS.
Junod 2011;
Breast Not performed
Substantial increase in breast cancer
incidence in France without a
corresponding increase in mortality,
which largely reflects an increase in
overdiagnosis
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Study;
Cancer
Type;
Study Design
Study
Population;
Time Period Description of Methods Reference Population
Screening
Schedule
Kalager
2012;
Breast;
Ecologic
Norwegian
women 50-79;
1996-2005
(screening)
1986-2005 (pre-
screening)
Calculated incidence rate ratios (current screening/historical
screening)/(current nonscreening/historical nonscreening)
including women up to age 79, expecting to see a
compensatory deficit in incidence in this age group.  Also
analyzed just one county that had 10 years of follow-up after
screening started.
Contemporary control
group in counties not
offered screening
(1996-2005) and a
historical non-screening
group (1986-1995), and
a historical group
offered screening
(1986-1995)
2-view
mammography
biennially from
50-69, 77%
participation rate
Morrell 2010;
Breast;
Ecologic
New South
Wales women
50-69;
1991-2001
(screening)
1972-1990 (pre-
screening)
Calculated expected incidence rates with two methods, by
interpolating incidence of women 50-69 from women <40 and
>80 not offered screening, and by assuming continuation of
incidence trend in women 50-69 from pre-screening period.
Adjusted expected incidence for HRT use, nulliparity, obesity
rates.  Compared expected to observed rates.
Used linear regression
to model expected
incidence in women 50-
69 based pre-screening
trends and based on
women<40 and >80 not
offered screening
Biennial
mammography,
60% participation
Njor 2013;
Breast
Cohort
Women 56-79 in
Copenhagen and
59-78 in Funen;
1991/1993-2009
Compared cumulative incidence in screening regions to
expected incidence in absence of screening, including women
up to 8 years post-screening in overall incidence estimates.
Expected incidence determined from historical screening-
region control group adjusted for the change in incidence from
historical to contemporary non-screening control groups, and
using an interaction term to account for differences in baseline
incidence trends between regions (interaction between region
and period).
3 control groups: a
contemporary control
group from non-
screening regions, a
historical control group
from current screening
regions, and a historical
control from current
non-screening regions
Biennial
mammography
ages 50-69, 71-
84% first round
participation
Paci 2006;
Breast
Cohort
Women 50-74 in
Italy;
10-year period
between 1986-
2006, dates vary
by region
Used Poisson regression to predict incidence rates in six
screening regions that had at least 5 years of screening
implementation based on incidence in the pre-screening
period.  Corrected the observed cases statistically for lead time
and compared to expected
Modeled expected
incidence from pre-
screening trends Not provided
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Study;
Cancer
type
Screening in
Reference
Population
Management of Potential
Confounders
Management
of Lead Time
Calculation of
Overdiagnosis
A.Includes
DCIS?
B.Reports
preferred
outcome?
Magnitude of
Overdiagnosis
(95% CI)
Kalager
2012;
Breast Not provided
Current screening and non-screening
incidences compared to historical
screening and non-screening
incidences to account for temporal
trends
Including
women up to
79 years in
incidence
estimate, with
up to 10 years
follow-up
post-screening
(excess cases)/
(observed cases)
during
screening,
including
women up to 79
A. No
B. No
Entire country: 25%
(19-31%)
County w/10yrs
follow-up: 18% (11-
24%)
Morrell
2010;
Breast Not provided
Population attributable fractions to
HRT use, obesity, and nulliparity were
calculated and combined, assuming the
lowest level of risk factor before the
study period and the highest during the
study period, and expected incidence
was adjusted
Statistical
adjustment for
lead time of
2.5 and 5
years
(excess cases)/
(expected cases)
during screening
A. No
B. No
Interpolation model:
42%
Extrapolation model:
30%
(5-year lead time)
Njor
2013;
Breast
In 2000, 3% of
women 50-69 in
non-screening
regions had
screening or
diagnostic
mammograms
Controlled for differing temporal
trends in incidence between screening
and non-screening regions with
interaction term in regression analysis
Up to 8 years
follow-up
post-screening
(excess cases)/
(expected cases)
during screening
and 8-years
post-screening
A. Yes
B. No
Copenhagen: 6% (-10
to 25%)
Funen: 1% (-7 to 10%)
Pooled: 2.3% (-3 to
8%)
Paci
2006;
Breast Not provided
Adjusted for age in poisson regression
model
statistical
adjustment,
using MST of
3.7 years for
ages 50-59
and 4.2 years
for 60-74
(excess cases)/
(expected cases)
during screening
A. Yes
B. No
36.2% (34-39%)
before adjustment for
lead time
4.6% (2-7%) after
adjustment for lead
time
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Study;
Cancer type
Considerations of Uncertainty/
Sensitivity Analyses Results of Sensitivity Analyses Conclusions
Kalager
2012;
Breast
Second analysis to account for lead time in
a different way, excluded all cases detected
at first screening round and compared
incidence in current screening group with
women 2 and 5 years older in historical
screening groups
Lead time 5 years: 15% (8-23%)
Lead time 2 years: 20% (13-28%)
Mammography screening entails a
substantial amount of overdiagnosis
Morrell
2010;
Breast Also used 2.5 year lead time
Interpolation model: 51%
Extrapolation model: 36%
(lead time 2.5yrs)
Overdiagnosis of invasive breast cancer
attributable to mammography is
substantial, and estimates similar to recent
estimates from other screening programs
Njor 2013;
Breast
Performed analyses with only women with
>8 years follow-up, and corrected the
analyses to estimate overdiagnosis in
participants only
8+ years follow-up: Copenhagen: 3.4%
(-14 to 25%)
Funen: 0.7% (-8 to 12%)
Participants only: Copenhagen: 8%
Funen: 2%
Overdiagnosis most likely 2.3%, and
study indicates that at least 8 years of
follow-up were needed to compensate for
the excess during screening.
Paci 2006;
Breast
performed sensitivity estimate using 95%
CI upper limit of lead time (4.8 years) 2.80%
Remaining excess of cancers after
individual correction for lead time was
<5%.
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Study;
Cancer
Type;
Study Design
Study Population;
Time Period Description of Methods
Reference
Population
Screening
Schedule
Peeters 1989;
Breast;
Ecologic
Women in Nijmegen,
Netherlands;
1975-1986
Compared incidence during six screening rounds among
women in Nijmegen to neighboring city with no mass
screening program.
Women in
neighboring city,
Arnhem
Biennial
mammography for
women 35+, 65-
85% participation
Puliti 2009;
Breast;
Cohort
Women 60-69 in
Florence;
1990-2005
Calculated expected incidence based on pre-screening
incidence trends in the screened cohort using Poisson
regression and forcing the parameter for annual
percentage change to 1.2%.  Compared expected
incidence with observed incidence
Modeled expected
incidence from pre-
screening trends
Biennial
mammography for
women 50-69, 60-
70% participation
Puliti 2012;
Breast;
Cohort
Women 60-69 in
Florence;
1991-2007
Compared incidence rates in screening attenders and
non-attenders using poisson regression models adjusted
for 5-year age group, marital status and deprivation
class.  Incidence rate ratio for women 60-69 determined
overdiagnosis
Screening non-
attenders in the first
two screening rounds
Biennial
mammography for
women 50-69, 56-
70% participation
Svendsen
2006;
Breast;
Ecologic and
Cohort
Women 50-69 in
Copenhagen and Fyn,
Denmark;
1991-2001
(screening), 1979-
1990 (pre-screening)
Compared age-standardized incidence rates in
Copenhagen and Fyn to the rest of Denmark and in the
pre-screening period of the screening regions.
Calculated confidence intervals for the pre-screening
incidence rates with quadratic and linear regression.
Women in the rest of
Denmark without
organized screening
programs, and pre-
screening trends in
the screening
counties
Biennial
mammography for
women 50-69
Zahl 2004;
Breast;
Ecologic
Women 50-74 in
Akershus, Oslo,
Rogaland, Hordaland,
Norway;  1991-5 (pre-
screening), 1995-2000
(screening)
Women 50-79 in
Sweden; 1971-85 (pre-
screening), 1986-2000
(screening)
Norway: Used Poisson regression to compare incidence
rates during screening in 2000 to rates in the same
regions in 1991, after demonstrating no increase in
incidence during the pre-screening period 1991-5
Sweden: Used Poisson regression to compare incidence
in entire country during screening to pre-screening
period
Women in screening
regions in pre-
screening periods
Biennial
mammography 50-
69, 75% average
participation in
both countries
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Study;
Cancer
Type
Screening in
Reference
Population
Management of Potential
Confounders
Management of
Lead Time
Calculation of
Overdiagnosis
A.Includes
DCIS?
B.Reports
preferred
outcome?
Magnitude of
Overdiagnosis
(95% CI)
Peeters
1989;
Breast Not provided
Compared breast cancer incidence
in Nijmegen and Arnhem pre-
screening and mortality from
1970-79 and found them to not be
statistically different, thus
concluded Arnhem was an
appropriate control Did not
(excess cases)/
(expected cases)
during screening
A. Yes
B. No
overall: 11%
1975-79: 30%
1972-82: 3%
1983-86: 1%
Puliti
2009;
Breast Not provided
Adjusted for age in poisson
regression model
5-10 year follow-up
post-screening for
the oldest cohorts
(ages 60-69)
(excess cases)/
(expected cases)
during screening
and 5-years
post-screening
A. Yes
B. No 1% (-5 to 7%)
Puliti
2012;
Breast
16% of control
group attended
screening
during study
period
adjusted for age, marital status,
and deprivation index
(representing area-level
socioeconomic status)
5-14 year follow-up
post-screening for
women 60-69
(excess cases)/
(expected cases)
during screening
and 5-14 years
post-screening
A. Yes
B. No 10% (-2 to 23%)
Svendsen
2006;
Breast
Opportunistic
screening in
Denmark is
minimal Age-standardized incidence rates Did not Not calculated
A. No
B. No
None (screening
incidence w/in 95% CI
of pre-screening
trends)
Zahl
2004;
Breast
Norway: not
discussed
Sweden: in
some regions
women offered
screening at
ages 70-74
Adjusted for age, demonstrated
no increase in incidence during
pre-screening period needing
adjustment
Norway: up to 4
years of follow-up
post-screening in
ages 70-74
Sweden: up to 14
years of follow-up
post-screening
(ages 70-79)
(excess cases)/
(expected cases)
during screening
A. No
B. No
Norway: 56% (42-
73%) increased
incidence with no
post-screening drop
Sweden: 45% (41-
49%)  increased
incidence with 12%
drop
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Study;
Cancer type
Considerations of Uncertainty/
Sensitivity Analyses Results of Sensitivity Analyses Conclusions
Peeters
1989;
Breast Not performed
There is no evidence that screening
programs using mammography constitute
a significant risk for overdiagnosis of
breast cancers
Puliti 2009;
Breast
Performed sensitivity estimate assuming no
trend of increasing baseline incidence 13% (7-19%)
Although estimate of overdiagnosis was
very sensitive to pre-screening trend
estimates, data show that the degree of
overdiagnosis was nearly zero and most
likely less than 13%
Puliti 2012;
Breast
Re-analyzed with exclusion of 34 women
who were non-attenders who had a
diagnosis of breast cancer within 6 months
of invitation 15%
Overall cost to save one life corresponds
to no more than one overdiagnosed tumor
Svendsen
2006;
Breast Not performed
The early detection program of this study
did not result in any major overdetection
Zahl 2004;
Breast Not performed
Without screening one third of all
invasive breast cancers in women 50-69
would not have been detected in the
patients' lifetime.
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Study;
Cancer
Type;
Study Design
Study Population;
Time Period Description of Methods
Reference
Population
Screening
Schedule
Zahl 2012;
Breast;
Ecologic
women 50-79 in
Norway counties
Akershus, Oslo,
Rogaland, and
Hordaland;
1991-5 (pre-
screening), 1995-2009
(screening)
Used Poisson regression to estimate changes in
incidence of breast cancer in screening regions
compared to pre-screening period in same regions.
Looked for a decrease in incidence in women 70-74
post-screening
Women in screening
regions in pre-
screening period
Biennial
mammography 50-
69
Ciatto 2005;
Prostate;
Cohort
Italian men 60-74;
1991-4 (screening)
1995-2000 (post-
screening)
Compared observed cancers in screened cohort to
number expected with standardized incidence ratios.
Expected cancers calculated based on Tuscan Cancer
Registry incidence rates
Entire population in
Tuscany Cancer
Registry, including
study cohort
Two biennial
screening rounds of
DRE+TRUS or
PSA, with random
sextant biopsy for
PSA>10ng/ml and
directed biopsy for
suspicious findings
on DRE/TRUS
Hugosson
2000;
Prostate;
Cohort
Swedish men 64-66;
1980-1996
Determined incidence in study cohort of men 64-66 in
1995 who had PSA>3 on screening test.  Compared with
incidence in cohort of men age 67 in 1980 who were
followed until 1995, who also had PSA>3 on sample
drawn in 1980 that was not analyzed until 1996.
Swedish men born in
1913, age 67 when
PSA sample was
drawn but not
analyzed until 1980,
then followed for
cancer incidence until
1995
One-time PSA with
threshold 3ng/ml
for referral to DRE,
TRUS and sextant
biopsies
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Study;
Cancer
type
Screening in
Reference
Population
Management of Potential
Confounders
Management
of Lead Time
Calculation of
Overdiagnosis
A.Includes
DCIS?
B.Reports
preferred
outcome?
Magnitude of Over-
diagnosis (95% CI)
Zahl
2012;
Breast
Some
opportunistic
screening
occurred in
pre-screening
period
Adjusted for age, county, population
growth and baseline incidence trend.
Demonstrated no change in baseline
incidence in women too young for
screening. Discussed how HRT use as
indicated by sales of HRT was stable
from 1991-3 to 2007-9 while the
number of potential users increased by
33%, concluding that HRT not an
important cause of breast cancer in
Norway
Up to 14 years
of follow-up
post-screening
(ages 70-79)
(excess cases)/
(expected cases)
during screening
A. Yes
B. No
Confirmed 50%
incidence growth from
Zahl 2004, with non-
significant drop of 7%
in women 70-74
Ciatto
2005;
Prostate
Reference
population
includes
screened study
cohort.  Small
amount of
opportunistic
screening also
noted in
Florence. Adjusted for age
7-9 year
follow-up
post-screening
(excess cases)/
(expected cases)
during screening
and 9-years
post-screening
A. n/a
B. No 66% (40-100%)
Hugosson
2000;
Prostate n/a Not performed n/a n/a
A. n/a
B. No
None.  Men in
screened cohort had
lower cancer incidence
(22%) at one-time
PSA screening than
did men in control
cohort (32.9%)
followed over 15
years.
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Study;
Cancer type
Considerations of Uncertainty/
Sensitivity Analyses Results of Sensitivity Analyses Conclusions
Zahl 2012;
Breast Not performed
After 14 years of mammography
screening, there is a 50% increase
incidence of breast cancer that cannot be
explained by early diagnosis or use of
HRT, but that must instead be due to
overdiagnosis.
Ciatto 2005;
Prostate Not performed
High rates of overdiagnosis are confirmed
for a screening experience adopting a non-
aggressive protocol.
Hugosson
2000;
Prostate Not performed
Underdiagnosis rather than overdiagnosis
is the case at least with one-time
screening.
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Study;
Cancer
Type;
Study Design
Study
Population;
Time Period Description of Methods
Reference
Population
Screening
Schedule
Tornblom
2010;
Prostate;
Cohort
Men 55-70 in
Stockholm,
Sweden;
1988-2000
Compared cumulative incidence in men screened with PSA
who then underwent DRE and TRUS (in 1988) to a reference
population of men who had a PSA sample taken in the 1980
that was analyzed later.
Men age 67 in
Gothenburg
participating in the
Study of Men Born in
1913
PSA, DRE and
TRUS with
biopsies for
abnormal findings
on DRE, TRUS or
PSA>10ng/ml
Zappa 1998;
Prostate;
Cohort/
Modeling
Men 60/65
otherwise
similar to men
participating in
CSPO study in
Florence;
Not provided
Calculated expected age-specific incidence based on rates
from Tuscany Cancer Registry 1990-1, assuming 2% increase
per year.  Compared to incidence in hypothetical cohort of
men aged 60 based on incidence of screen-detected and
interval cancers in two rounds of screening in CSPO study
Men in Tuscan
Cancer Registry
Five biennial PSA
tests with 4 ng/ml
threshold
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Study;
Cancer
type
Screening in
Reference
Population
Management of
Potential
Confounders Management of Lead Time
Calculation of
Overdiagnosis
A.Includes
DCIS?
B.Reports
preferred
outcome?
Magnitude of Over-
diagnosis (95% CI)
Tornblom
2010;
Prostate
PSA screening in
Sweden was
infrequent Not performed
Follow-up beyond when
incidence in reference
population equaled that of
screened population Not calculated
A. n/a
B. No
None (incidence in
reference population
surpassed that of
screened population)
Zappa
1998;
Prostate
Opportunistic
screening in Florence
is negligible before
and through the study
period Not performed
4 years follow-up post-
screening
(excess cases)/
(expected cases)
during screening
and 4-years
post-screening
A. n/a
B. No
age 60: 25% (19-32%)
age 65: 65% (58-73%)
Study;
Cancer type
Considerations of Uncertainty/
Sensitivity Analyses Results of Sensitivity Analyses Conclusions
Tornblom
2010;
Prostate Not performed
The early detection program of this study
did not result in any major overdetection
Zappa 1998;
Prostate
Also considered constant annual incidence
over time
Age 60: 51% (44-59%)
Age 65: 93% (85-101%)
Screening for prostate cancer associated
with a relevant risk of overdiagnosis.
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Appendix Table 7: Criteria for Evaluating Risk of Bias and Strength of Evidence for Ecologic and Cohort Studies
Study
Cancer
type
Probability of
Selection
Bias and
Confounding
Probability of
Measurement
Bias
Considerations
of Uncertainty
Overall
Risk of
Bias
Time
Frame Analysis Directness
External
Validity Precision
H/M/L H/M/L G/F/P H/M/L G/F/P G/F/P G/F/P G/F/P G/F/P/CD
Bleyer 2012 breast M M G M G G F G CD
Duffy 2010 breast M M P M NA P P F CD
Falk 2013 breast H L F H G G F F F
Hellquist 2012 breast M M P M NA P P P F
Jorgenson 2009 (BMJ) breast M M P M F G F F G
Jorgenson 2009 (BMC) breast M M P M F G F F CD
Junod 2011 breast M M P M F P F F F
Kalager 2012 breast M L F M F P F F F
Morrell 2010 breast M M F M NA P P F CD
Njor 2013 breast M M P M F P F F F
Paci 2006 breast M M F M NA P P F F
Peeters 1989 breast H M P H P P F P CD
Puliti 2009 breast M M F M F P F F F
Puliti 2012 breast H M P H F P F F F
Svendsen 2006 breast M M P M P P F F CD
Zahl 2004 breast M M P M F G F F F
Zahl 2012 breast M M P M G G F F CD
Ciatto 2005 prostate M M P M F P F F P
Hugosson 2000 prostate H M P H G G F F CD
Tornblom 2010 prostate H H P H G G F F CD
Zappa 1998 prostate M M F M F P F P F
Criteria for evaluating Strength of Evidence are bolded.  Abbreviations: H, high; M, moderate; L, low; G, good; F, fair; P, poor; CD, cannot determine.
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Appendix Table 8: Evidence Table of Randomized Controlled Trial Follow-Up Studies
Study
Cancer Type
Study Population
Time Period
Post-Study Length
of Follow-Up Screening Schedule
Baseline
Characteristics of
Study Groups
Contamination
Screening in Control
Group
Zackrisson 2006
Breast
Swedish women 55-
69 in Malmo
1976-1986 15 years
5-6 rounds of
mammography every
18-24 months, 70-
74% attendance Not reported
During trial period,
24% of control group
underwent
mammography
Study
Cancer Type ITT analysis?
Includes
DCIS?
Reports
Preferred
Outcome?
Calculation of
Overdiagnosis
Magnitude of
Overdiagnosis
(95% CI) Conclusions
Zackrisson
2006
Breast Not reported Yes No
(excess cases)/
(control cases)
during trial and
15 years
follow-up 10% (1 to 18%)
Fifteen years after the Malmo trial
the rate of overdiagnosis was 10%
in women 55-69.
Appendix Table 9: Criteria for Evaluating Risk of Bias and Strength of Evidence for Follow-Up of a Randomized Controlled Trial
Study
Cancer
Type
Probability of
Selection Bias
Probability of
Measurement Bias
Potential for
Confounding
Overall
Risk of Bias
Time
Frame Analysis Directness
External
Validity Precision
H/M/L H/M/L H/M/L H/M/L G/F/P G/F/P G/F/P G/F/P G/F/P
Zackrisson 2006 breast L M L L G P F F F
Criteria for evaluating Strength of Evidence are bolded.  Abbreviations: H, high; M, moderate; L, low; G, good; F, fair; P, poor.
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